Review

Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults

Małgorzata Krzystek-Korpacka 1,*,†, Radosław Kempiński 2, Mariusz Bromke 1 and Katarzyna Neubauer 2,*,†

1 Department of Medical Biochemistry, Wrocław Medical University, Chalubinskiego 10, 50-368 Wrocław, Poland; mariusz.bromke@umed.wroc.pl
2 Department of Gastroenterology and Hepatology, Wrocław Medical University, Borowska 213, 50-556 Wrocław, Poland; radoslaw.kempinski@umed.wroc.pl
* Correspondence: malgorzata.krzystek-korpacka@umed.wroc.pl (M.K.-K.); katarzyna.neubauer@umed.wroc.pl (K.N.)
† These authors contributed equally to this work.

Received: 5 May 2020; Accepted: 30 May 2020; Published: 2 June 2020

Abstract: Mucosal healing (MH) is the key therapeutic target of inflammatory bowel disease (IBD). The evaluation of MH remains challenging, with endoscopy being the golden standard. We performed a comprehensive overview of the performance of fecal-, serum-, and urine-based biochemical markers in colonic IBD to find out whether we are ready to replace endoscopy with a non-invasive but equally accurate instrument. A Pubmed, Web of Knowledge, and Scopus search of original articles as potential MH markers in adults, published between January 2009 and March 2020, was conducted. Finally, 84 eligible studies were identified. The most frequently studied fecal marker was calprotectin (44 studies), with areas under the curves (AUCs) ranging from 0.70 to 0.99 in ulcerative colitis (UC) and from 0.70 to 0.94 in Crohn’s disease (CD), followed by lactoferrin (4 studies), matrix metalloproteinase-9 (3 studies), and lipocalin-2 (3 studies). The most frequently studied serum marker was C-reactive protein (30 studies), with AUCs ranging from 0.60 to 0.96 in UC and from 0.64 to 0.93 in CD. Fecal calprotectin is an accurate MH marker in IBD in adults; however, it cannot replace endoscopy and the application of calprotectin is hampered by the lack of standardization concerning the cut-off value. Other markers are either not sufficiently accurate or have not been studied extensively enough.

Keywords: mucosal healing; inflammatory bowel disease; ulcerative colitis; Crohn’s disease; fecal calprotectin; biomarker; endoscopy; c-reactive protein

1. Introduction

Inflammatory bowel disease (IBD), encompassing ulcerative colitis (UC) and Crohn’s disease (CD), are lifelong, potentially devastating conditions of the gastrointestinal tract, and are characterized by a relapsing–remitting course and heterogeneous clinical presentation with extraintestinal manifestations. Although their pathogenesis remains not fully elucidated, a crucial role seems to be played by an interaction of genetic, epigenetic, immunological, and environmental factors. The uncertainty and complexity of IBD pathogenesis result in the absence of a single diagnostic tool, and what is the most vital, the absence of an effective causative therapy [1,2]. This, in turn, drives the search for better therapeutic goals, and in parallel, the dynamic development of new therapeutic agents. In this respect, mucosal healing (MH) in IBD is gaining increasing attention. MH seems to be a better prognostic indicator of the disease outcome compared to clinical scores. In UC, it is associated with a lower risk of clinical relapse, hospitalization, need for immunosuppression and colectomy, and colitis-associated neoplasia [3–8]. In CD, MH has been significantly associated with less severe inflammation after
five years, a decreased risk of future steroid treatment, and lower rates of surgical resection [4,9–11]. The importance of achieving MH during therapy has been repetitively shown in numerous clinical trials, such as ACCENT [12], SONIC [13], and EXTEND [14].

IBD activity can be evaluated on several levels: clinical, biochemical, macroscopic (endoscopy), and microscopic (histology). However, clinical remission in an IBD patient does not necessarily imply MH, and vice versa, some patients with no visible inflammatory changes on an endoscopy report gastrointestinal symptoms, probably due to concomitant functional disorder of the gut. Histological remission is difficult to assess, especially in CD, in which the inflammation may be patchy and the lesions are not continuous (skip lesions) and are thus easily missed by the biopsy. Moreover, in the case of no visible macroscopic changes, it is hard to establish a representative tissue to be sampled for biopsy to confirm histological healing of the mucosa. The natural way to assess the effectiveness of the therapy is by confirming the resolution of lesions via endoscopy. Indeed, the simplest and most common MH definition applied in clinical practice is the absence of inflammation as judged by endoscopists [15]. Many scales have been devised for the objective classification of endoscopic findings. The most often used score for the evaluation of treatment efficacy in clinical trials, although not validated, is the Mayo Endoscopic Score (MES) [16,17], where MH is defined as MES ≤ 1. However, the guidelines of the European Crohn’s and Colitis Organization, as well as the Japanese Society of Gastroenterology, restrict complete endoscopic remission to a score of 0 (normal or completely healed mucosa) [18–20]. The only two indices that received formal validation in UC are the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) [21] and the Ulcerative Colitis Colonoscopic Index of Severity (UCCIS) [22]. It ought to be stressed that the application of different indices and the lack of standardization concerning the MH definition complicates the interpretation of data reported by various authors. A summary of the most important endoscopic scales for the evaluation of disease severity in UC is shown in Table 1.

Table 1. Selected endoscopic disease activity indices for ulcerative colitis.

| Endoscopic Activity Indices | Parameter | MES [16] | UCEIS [21] | UCCIS [22] |
|-----------------------------|-----------|----------|------------|------------|
| Erythema                    | +         |          | +          |            |
| Granularity                 |           |          | +          |            |
| Vascular pattern            | +         | +        | +          |            |
| Friability                  | +         | +        |            |            |
| Erosions                    | +         | +        |            |            |
| Ulceration                  | +         | +        |            |            |
| Exudate                     |           |          |            |            |
| MH definition               | 0–1       | nd       | nd         |            |
| Validation                  | +         |          |            |            |

MES, Mayo Endoscopic Subscore; UCEIS, Ulcerative Colitis Endoscopic Index of Severity; UCCIS, Ulcerative Colitis Colonoscopic Index of Severity; MH, mucosal healing; nd, not defined.

In contrast to UC, inflammatory changes in CD can also appear proximal to the terminal ileum. Moreover, a deeper layer of the gut wall can be involved with the formation of fistulas. The evaluation of the upper digestive tract, small intestine, and non-luminal CD can be performed with upper endoscopy, imaging techniques (magnetic resonance/computed tomography), or with capsule endoscopy. It must be highlighted, that non-invasive and widely available ultrasonography, namely simple intestinal ultrasonography or ultrasonography with contrast enhancement, is a valuable diagnostic tool for evaluating the disease activity and extent [18]. A standard ileocolonoscopy allows for the evaluation of injuries in the luminal mucosa and the detection of potential stenosis. Endoscopic activity may be reliably scored using either the Crohn’s Disease Endoscopic Index of Severity (CDEIS) [23] or the Simple Endoscopic Score for Crohn’s Disease (SES-CD) [24]. Both scores have been prospectively validated and are highly reproducible with excellent inter-observer agreement. A CDEIS score of < 3 is defined as mucosal remission [25]. The calculation of the score is complicated and time-consuming, which impedes its application in daily practice. SES-CD is a simplified version of CDEIS, making it easier to calculate. It has been validated and compared to CDEIS, with which it has shown a strong
positive correlation \( (r = 0.938) \) [25]. Additionally, the SES-CD is correlated with both clinical parameters and inflammatory indices (C-reactive protein (CRP)) [26]. For clinical trials, an SES-CD value can be converted into a CDEIS value using the following formula: \( \text{CDEIS} = 0.76 \times \text{SES-CD} + 0.29 \) [24].

While remaining a golden standard in MH detection, endoscopy is an invasive technique that risks bowel perforation and is poorly accepted by patients. Moreover, it is not easily available, requiring both expensive equipment and an experienced endoscopist. As such, surrogate markers allowing for a non-invasive and inexpensive, but equally accurate, evaluation of mucosa are intensively searched for. Our goal was to provide an overview of MH markers in colonic IBD that have emerged during the last decade, as well as a summary of their performance to address the question of whether they are ready to replace endoscopy in MH evaluation. Collected evidence shows that fecal calprotectin remains the closest to a “perfect” MH marker; however, the application of which is hampered by the lack of standardization concerning the optimal cut-off value. Although some of the emerging MH markers seem to be promising, confirmatory studies and validation are needed.

2. Methods

A systematic review was conducted in March 2020 and included manuscripts published from January 2009 in the English language. Through their respective websites, Pubmed, Web of Knowledge, and Scopus databases were queried with a set of 11 inclusion expressions. To prepare queries, the following expressions “mucosal healing”, “inflammatory bowel disease”, “inflammatory bowel diseases”, “ulcerative colitis”, “Crohn’s disease”, “Crohn”, “mucosal inflammation”, “bowel inflammation”, “colonic inflammation”, and “colonoscopy” were used and each of them was matched through an operator AND with a “marker” expression. Query results were cross-searched and cleaned of duplicates. In the following title screening step, publications concerning non-IBD, pediatric IBD, non-colonic CD, unspecified IBD, experimental studies (animal and in vitro), microbiota-related, hematological, on tissue-based markers, on non-MH markers, and non-original articles were excluded. The same criteria were applied for the abstract screening, and finally, for the full-text screening. At the full-text screening step, an additional description of the markers’ performance, in terms of their accuracy and/or sensitivity and specificity, was required.

At each step, the article selection was verified by a second investigator. No authors were contacted for further data. The following data were retrieved from the reviewed publications: the type of potential marker and its source (serum/plasma, feces, urine), the method of assessment and assay manufacturer (in the case of calprotectin), the IBD phenotype (CD or UC, or mixed IBD cohort), study population including the number of patients with MH, additional characteristics of the evaluated cohort if specific (clinical remission, treatment), the score used for the evaluation of endoscopic findings and the MH definition applied, the correlation between the evaluated marker and endoscopic findings, and the marker characteristics. Regarding the marker characteristics, the following data were included (if available): areas under the receiver operating characteristics (ROC) curves (AUCs) and/or sensitivities and specificities with a corresponding cut-off value, and a correlation coefficient. Predictive values were not included since they are dependent on the condition prevalence, which differed between studies. For this review, the following interpretation of AUCs was adopted: AUC = 0.50–0.75 is a fair overall accuracy, AUC = 0.75–0.92 is a good overall accuracy, AUC = 0.92–0.97 is a very good overall accuracy, and AUC = 0.97–1.00 is an excellent overall accuracy. Studies exclusively reporting correlation coefficients were not included in the proper review. However, to support the associations found by others, or conversely, to contradict them, some of those studies might be discussed in the text.

Analysis of the data was conducted according to PRISMA recommendations.

3. Results

Our search results are presented in Figure 1. Several potentially eligible articles did not provide data allowing for the evaluation of a marker’s performance, such as AUC or sensitivity and specificity at a given cut-off value, or the marker’s performance was evaluated based on the clinical disease
activity rather than the endoscopic one. As such, those articles were not included in the final synthesis. Finally, this systematic review was prepared based on 84 publications.

Figure 1. Flowchart presenting the selection process. IBD, inflammatory bowel disease; CD, Crohn’s disease; AUC, area under the receiver operating characteristics (ROC) curve.

3.1. Interpretative Synthesis of Data: Fecal Markers

3.1.1. Calprotectin

Although there is a wide range of biochemical, serological, immunological, genetic, epigenetic, and microbiological markers studied regarding IBD, fecal calprotectin (FC) is one of the few that was implemented in clinical practice and has been extensively used. Furthermore, it has a strong position in the international and local guidelines and can be used not only by gastroenterologists and general practitioners but also by patients at home.

Calprotectin, first described in 1980, is a 36 kDa zinc- and calcium-binding protein that belongs to the S100 family. The main source of calprotectin are neutrophils, and to a lesser extent, monocytes and macrophages. Calprotectin constitutes 60% of the soluble cytosolic proteins of neutrophils and it
is used as a marker of neutrophil turnover. It can be detected in different biological fluids, such as sera, saliva, and urine, as well as in feces. The concentration of the calprotectin in stool is proportional to the neutrophils’ migration to the gastrointestinal tract, and thus, calprotectin is the most broadly measured marker in feces [27].

In clinical practice, FC measurement is employed to differentiate between functional bowel disorders, mainly irritable bowel syndrome, and inflammatory bowel disease. In patients with IBD, it is applied as a valuable non-invasive tool to monitor the disease course in terms of evaluating disease activity and mucosal healing. It was repeatedly demonstrated that FC is a sensitive marker of mucosal inflammation in IBD and is related to the extent of inflammation in UC [28,29]. In Crohn’s disease, FC (cut-off: ≥ 70 µg/g) performed more accurately in the identification of endoscopically active disease (overall accuracy: 87%) than elevated CRP, blood leukocytosis, and CDAI (overall accuracy: 66%, 54%, and 40%, respectively) [30]. Likewise, in UC, FC detected endoscopically active disease with a very good overall accuracy (89%), better than the Clinical Activity Index, elevated CRP, and blood leucocytosis (overall accuracy: 73%, 62%, and 60%, respectively) [31]. FC may additionally serve as a very good marker in the differentiation of acute severe colitis from mild to moderate colitis (cutoff value: 782 µg/g, sensitivity: 84%, specificity: 88%, AUC: 0.92) [32].

FC is a factor that predicts the treatment response [33], as well as the future course of the disease, namely relapse and postoperative recurrence. It can predict remission maintenance in CD (cutoff value: 327 µg/g, sensitivity: 92.3%, specificity: 82.4%, AUC: 0.924) [34], but also a flare in UC (cutoff value: 114 µg/g, sensitivity: 76%, specificity: 85%) [35]. In UC patients treated with infliximab, a reduction in the concentration of FC predicted the remission of disease [36].

FC has also become an integral part of the complex patient evaluation in clinical trials testing novel therapeutic agents. At the same time, home assays designed for use by patients have been developed. Smartphone-based home FC test was evaluated by 56% of patients as easy to perform and more than 90% were satisfied with it. Furthermore, there was a close correlation between laboratory and home tests [37]. Smartphone-based testing is an example of implementing an e-health strategy in real-life practice and can be a very useful alternative method of monitoring IBD patients [38].

The performance of FC in the evaluation of CD activity seems to be accurate irrespective of the disease location [39]. However, patients with ulcers limited to the ileum had significantly lower FC levels than patients with ulcerations in the colon [40]. In another study, FC correlated with the affected surface but not with the ulcerated surface and disease location [41].

3.1.2. Fecal Calprotectin as a Marker of Mucosal Healing

Switching the approach to the therapeutic goals regarding IBD from clinical remission to MH resulted in the extensive assessment of FC as a non-invasive mucosal healing marker. This issue is further complicated by the definition of mucosal healing, which is far from being precise. The question arises whether an endoscopic evaluation is enough to diagnose MH, and if so, which score is optimal. Other tactics require the histologic confirmation of MH or a combination of both methods. Nevertheless, endoscopy is currently the prerequisite to diagnose mucosal healing. An alternative MH predictor is sought for this procedure, which is invasive, costly, and poorly accepted by patients.

The FC as an MH marker was evaluated in 44 eligible articles. The reported AUCs, allowing for the evaluation of the overall accuracy of a marker independently from a selected cutoff, ranged from fair to excellent overall accuracy for UC (0.70–0.99) and from fair to very good for CD (0.74–0.94) (Tables 2 and 3, respectively). Unfortunately, a large variation in the selected optimal cutoff values was noted, ranging from 13.9 to 918 µg/g for UC and from 71 to 918 µg/g for CD. The analysis of FC’s performance as an MH marker revealed that it displayed better sensitivity regarding CD than for UC, with respective median values of 83% against 79%, and better specificity for UC than for CD, with respective median values of 85% against 71%.
Table 2. Diagnostic performance of fecal calprotectin for MH detection for ulcerative colitis.

| Authors                  | N     | MH/Total | MH Definition | Marker Performance | Assay * |
|--------------------------|-------|----------|----------------|---------------------|---------|
|                          |       |          |                | AUC     | Cutoff (µg/g) | Sens. and Spec. | Type, Manufacturer |
| Carlsen et al. [42]      | 68/106| MES = 0 and GS ≤ 1 | 0.87 | ≤25 | 58% and 90% | ELISA, Calpro Ltd. |
| Jha et al. [43]          | 5/81  | MES ≤ 1   | 0.94 | 158 | 90% and 85% | ELIA, Phadia 100 Calprotectin |
| Jusué et al. [32]        | 30/48 | MES = 0   | 0.91 | 501 | 79% and 85%1 | rapid kit, Quantum Blue®, Bühlmann |
|                          |       |          | 0.921 | 1022 | 79% and 85%2 | 1low-range test; 2high-range test |
| Mak et al. [44]          | 23/61 | MES ≤ 1   | 0.78 | <250 | 77% and 67% | ELISA, Genova Diagnostics |
| Mine et al. [45]         | 45/60 | MES = 0   | 0.77 | 201 | 71% and 78% | EliA, Immunodiahnostik AG |
| Walsh et al. [46]        | 21/66 | UCEIS ≤ 1 | 0.92 | 187 | 100% and 67% | IBDoc® FCAL test, Bühlmann |
| Chen et al. [47]         | 12/44 | MES ≤ 2   | 0.96 | ≤250 | 85% and 100% | ELISA, Bühlmann Calprotectin |
| Kostas et al. [48]       | 39/149| MES = 0 ML absence (CD) | 0.96 | 174 | 92% and 87% | ELISA, EK CAL, Bühlmann |
|                          |       |          |                | 0.88    | 187        | 86% and 89% | rapid test, Quantum Blue®, Bühlmann |
| Patela et al. [50]       | 31/60 | MES ≤ 1   | 0.92 | 60 | 86% and 87% | EliA, na |
| Hiroaka et al. [51]      | 75/152| MES = 0   | 0.81 | <1841 | 78% and 69%1 | ELISA, Phical Calprotectin; |
|                          |       |          | 0.822 | <2242 | 79% and 78%2 | 1LATIA |
| Zittan et al. [52]       | 44/58 | MES = 0 SES-CD ≤ 3 | 0.91 | <100 | 71% and 91% | Bühlmann Quantum Blue Calprotectin High Range Immunoassay |
| (mixed UC and CD)        |       |          |                |         |           |                | |
| Lin et al. [54]          | na/52 | UCEIS < 3 | 0.97 | 918 | 88% and 75% | ELISA, Quantum Blue Calprotectin High Range Rapid Test |
| Lobatón et al. [55]      | 35/146| MES = 0   | 0.921 | 160 | 67% and 85%1 | Bühlmann ELISA |
|                          |       |          | 0.862 |       | 65% and 84%2 | 1QPOCT; Quantum Blue |
| Nancey et al. [56]       | 20/55 | RI ≤ 2    | 0.96 | 250 | 87% and 91% | ELISA, Bühlmann |
| Onal et al. [57]         | 30/60 | RI < 4    | 0.81 | 99.5 mg/L | 77% and 79% | ELISA Phi Cal |
| Schoepfer et al. [58]    | 54/228| mBS ≤ 1   | 0.94 | 57 | 90% and 91% | ELISA Phi Cal |
| Falvey et al. [59]       | na/65 | MES = 0   | 0.81 | 125 | 74% and 80% | ELISA CalPro |
| Kristensen et al. [60]   | 18/62 | MES = 0   | 0.88 | 61 | 84% and 83% | Calpro ELISA |

RI: Random Index; UCEIS: Upper Colonic Endoscopy Index Score; MES: Mesenteric E Colonic Score; GS: Gastrointestinal Score; SES-CD: Simple Endoscopic Score for Crohn’s Disease; mBS: Modified Bhutan Score; mL: Milliliter; IDK®: IDK Calprotectin ELISA; Quantum Blue High Range Rapid Test; Quantum Blue Calprotectin High Range Immunoassay; ELISA, EK CAL, Bühlmann; IDK® Calprotectin ELISA; ELISA, Quantum Blue Calprotectin High Range Rapid Test; ELISA, Phical Calprotectin; ELISA Phi Cal; ELISA, Bühlmann; ELISA, Calpro Ltd; ELISA, Immunodiahnostik AG; ELISA, Genova Diagnostics; ELISA, Phadia 100 Calprotectin; ELISA, Bühlmann; ELISA, Bühlmann Calprotectin; ELISA, Bühlmann; ELISA, Bühlmann; ELISA, na; ELISA, na; ELISA, Bühlmann; ELISA, Bühlmann; ELISA, Bühlmann; ELISA, Bühlmann; ELISA, Bühlmann.
| Authors                              | N  | MH/Total | MH Definition            | Marker Performance | Assay *                  |
|--------------------------------------|----|----------|--------------------------|--------------------|--------------------------|
|                                      |    |          |                          | AUC    | Cutoff (µg/g) | Sens. and Spec. | Type, Manufacturer |
| Kristensen et al. [60]               | 18 | 62       | MES = 0                  | 0.93   | 96          | 91% and 83%    | ELISA, Buhlmann   |
| Scaioli et al. [61]                  | 45 | 121      | MES = 0                  | 0.98   | 110         | 98% and 90%    | ELISA, Calprest   |
| Takashima et al. [62]                | 77 | 105      | MES ≤ 1                 | 0.82   | 200         | 77% and 72%    | ELISA PhiCal      |
| Theede et al. [63]                   | na | 120      | MES = 0<sup>1</sup> UCEIS = 0<sup>2</sup> | 0.88   | 192         | 75% and 88%<sup>1</sup> 79% and 87%<sup>2</sup> | ELISA, Buhlmann |
| Voiosu et al. [64]                   | 16 | 48 (mixed UC and CD) | MES = 0 SES-CD ≤ 3 | 0.77   | 30          | 94% and 50%    | Buhlmann Quantum Blue Reader® |
| Yamaguchi et al. [65]                | 94 | 105 (CR) | MES = 0<sup>1</sup> MES ≤ 1<sup>2</sup> | 0.64<sup>1</sup> 0.8<sup>2</sup>  | 194<sup>1</sup> 200<sup>2</sup> | 71% and 53%<sup>1</sup> 67% and 91%<sup>2</sup> | EliA Calprotectin 2, Thermo Fisher Scientific |
| Nakov et al. [66]                    | 50 | 116      | UCEIS = 0 and MES = 0    | 0.988  | 99          | 97% and 98%    | Quantum Blue® Calprotectin, Buhlmann Laboratories AG |
| Hart et al. [67]                     | 159 | 185   | MES ≤ 1                 | 0.722  | 170         | 65% and 69%    | ELISA, Buhlmann   |
| Karling et al. [68]                  | 34 | 88       | MES = 0                 | 0.707  | 63          | 67% and 68%    | CALPRO, Calprotectin ELISA Test |
| Yang Woon et al. [69]                | 7  | 29       | MES = 0                 | 0.88   | 201         | 82% and 100%   | ELISA, Buhlmann Laboratories AG |
| Ryu et al. [70]                      | 51 | 174      | MES = 0                 | 0.863  | 170         | 78.4% and 74.8% | ELISA, Thermo Fisher Scientific |
| Ryu et al. [70]                      | 59 | 174      | UCEIS ≤ 1               | 0.847  | 170         | 74.6% and 76.5% | ELISA, Thermo Fisher Scientific |

N, number of observations; MH, mucosal healing; MES, Mayo Endoscopic Subscore; GS, Goebes Score; RI, Rachmilewitz Index; SES-CD, Simple Endoscopic Score for Crohn’s Disease; UCEIS, Ulcerative Colitis Endoscopic Index of Severity; mBS, modified Baron Score; ML, mucosal lesions; UC, ulcerative colitis; CD, Crohn’s disease; CR, subpopulation of patients in clinical remission; LATIA, latex agglutination turbidimetric immunoassay; AUC, area under receiver operating characteristics (ROC) curve; Sens., sensitivity; Spec., specificity; na, not available. *, Names of assays as provided by the authors of the cited papers. Numbers in superscript indicate parameters corresponding with a given test or MH definition.
Table 3. Diagnostic performance of fecal calprotectin in MH detection for Crohn’s disease.

| Authors                  | N    | MH/Total | MH Definition | Marker Performance | Assay * | Type, Manufacturer                  |
|--------------------------|------|----------|---------------|--------------------|---------|-------------------------------------|
| Iwamoto et al. [71]      | 39/69| eSES-CD = 0 |               | 0.91 92             | Sens. and Spec. | 94% and 88% EliA, Calprotectin 2    |
| Lopes et al. [72]        | 19/29| SES-CD = 0  |               | 0.88 100            |         | 92% and 65% EliA, Calprotectin      |
| Chen et al. [47]         | 56/92| SES-CD     |               | 0.91 250            |         | 93% and 70% ELISA, Bühlmann Calprotectin |
| Vazquez-Maron et al. [73]| 22/71| SES-CD ≤ 2 |               | na 71              |         | 96% and 52% ELISA, Calprest®       |
| Arai et al. [74]         | 123  | SES-CD = 0  |               | 0.81 215            |         | 83% and 71% ELISA, PhiCal Calprotectin |
| Inokuchi et al. [75]     | 23/71| SES-CD = 0  |               | 0.82 180            |         | 87% and 71% ELISA, Phical Calprotectin |
| Jusué et al. [32]        | 24/52| SES-CD = 0  |               | 0.71 541           | 63% and 71% | Rapid Kit, Quantum Blue® Bühlmann low-range test; 2high-range test |
| Lin et al. [54]          | na   | CDEIS < 6  |               | 0.74 918            |         | 50% and 100% ELISA, Quantum Blue Calprotectin High Range Rapid Test |
| Lobatón et al. [76]      | 40/115| CDEIS ≤ 3  |               | 0.941 2741          | 76% and 97% | 1Bühlmann ELISA, 2QPOCT-Quantum Blue |
| Nancey et al. [56]       | 40/78| SES-CD ≤ 2 |               | 0.77 250            |         | 78% and 71% ELISA, Bühlmann         |
| Schaffer et al. [77]     | 51/136| SES-CD ≤ 3 |               | 0.83 250            |         | ELISA assay RIDASCREEN® CALPROTECTIN, R-Biopharm AG |
| Falvey et al. [59]       | na/108| SES-CD ≤ 3 |               | 0.74 125            |         | 71% and 71% ELISA CalPro           |
| Karczewski et al. [78]   | 5/55 | CDEIS < 3  |               | na 76              | 96% and 80% | CalproLab™ ELISA kit               |
| Björksten et al. [26]    | 23/126| SES-CD ≤ 2 |               | 0.85 100            |         | 84% and 74% ELISA, PhiCal          |

N, number of observations; MH, mucosal healing; SES-CD, Simple Endoscopic Score for Crohn’s Disease; eSES-CD, extended Simplified Endoscopic Activity Score for Crohn’s Disease (eSES-CD); CDEIS, Crohn’s Disease Endoscopic Index of Severity; AUC, area under receiver operating characteristics (ROC) curve; Sens., sensitivity; Spec., specificity; na, not available.

* Names of assays as provided by the authors of the cited papers. Numbers in superscript indicate parameters corresponding with a given test.
Summarizing, FC may be a useful tool to detect MH; however, consensus on the cutoff value is still missing, which can be explained, at least partly, by the inter-assay variability. Carlsen et al. [42] demonstrated that FC may serve as a good indicator of deep remission at a cutoff value at ≤ 25 mg/kg, where deep remission in this study was defined using combined endoscopic (MES < 1) and histologic (Goebes Score ≤ 1) indices. Additionally, the results of the study confirmed the utility of FC as a marker of endoscopically and histologically active IBD with a cutoff of > 230 mg/kg. In turn, when the concentrations of FC are at the level of 25–230 mg/kg, researchers have suggested that endoscopy should be performed if it is needed to optimize the therapy. The performance of other markers (hemoglobin, CRP, orosomucoid, erythrocyte sedimentation rate, albumins) or the Simple Clinical Colitis Activity Index (SCCAI) as predictors of deep remission and inflammatory activity was not accurate. Jha et al. proposed 158 mg/kg for the cut-off value of FC when the definition of mucosal healing was MES ≤ 1 [43]. Moreover, in a recently published study, Walsh et al. showed that FC correlated strongly with UC activity in terms of the endoscopic (UCEIS), histologic (Nancy score), and combined evaluations. Furthermore, they identified the optimal threshold of FC concentration for histologic remission to be 72 µg/g, and for the endoscopic and combined criteria, the cutoff was 187 µg/g [46]. Zittan et al. [52] also demonstrated that low levels of FC (<100 µg/g) closely correlated not only with endoscopic indices of IBD activity but also with histological remission (Goebes score < 3.1). Lee et al. [49] showed that the concentration of FC correlated better with UCEIS than with the Mayo score in a group of 181 UC Korean patients. Besides the correlation with endoscopic indices, a strong correlation between FC and both clinical activity index and CRP was shown. The FC evaluation had similar performance characteristics to the fecal immunochemical test (FIT); however, its specificity for identifying mucosal healing could be improved by the combined assessment of FC, FIT, and clinical symptoms [79]. Patel et al. [50] showed that there is a correlation between the FC level and disease extent but also with the worsening of activity in terms of clinical, endoscopic, and histological indices. Furthermore, these authors demonstrated that patients with mucosal healing, defined as MES ≤ 1, had significantly elevated FC if their disease was histologically active (Nancy score ≥ 2). In another study, almost 12% of patients with endoscopic remission had histologically active disease, which was accompanied by significantly elevated FC [80]. In the same study, a baseline FC level of ≥ 321 mg/g was predictive of disease relapse at the 6- and 12-month follow-up [80]. Björkesten et al. [26] analyzed a group of 64 CD patients and found that FC, in contrast to CRP, CDAI, and the Harvey–Bradshaw Index (HBI), was a good marker of MH. However, 13% of patients with endoscopically active disease had a normal FC value. Hence, they attempted to create a score by incorporating all the aforementioned indices. Despite some advantages from the combination of HBI and FC, these parameters were not superior to the FC alone. As 24% of CD patients and 15% of UC patients have undefined disease activity according to their FC level (100–250 µg/g), it has been proposed that incorporating FC into the disease activity evaluation, together with clinical indices and CRP, would serve as a better marker of disease activity than FC alone [81].

3.1.3. Limitations of Fecal Calprotectin

FC may be elevated in many pathological conditions, such as gastrointestinal infections, gastric and colonic malignancies, eosinophilic colitis, lymphocytic colitis, and coeliac disease [82]. For instance, in a group of 870 outpatients referred for colonoscopy, an increased level of FC was demonstrated in 85% of patients with colorectal cancer and in 81% of patients with inflammatory conditions [83]. In turn, pregnancy does not affect the concentration of FC, and thus, its determination might be a useful non-invasive marker for monitoring the disease activity in pregnant IBD patients [84].

Multiple additional factors affect the level of FC and they all ought to be included when interpreting the result of the FC measurement.

Age, as well as concomitant medical treatment with proton pump inhibitors, nonsteroidal anti-inflammatory drugs, and acetylsalicylic acid, can all cause an increased concentration of FC. Correspondingly, Lundgren et al. [85] showed that around one-third of patients with a normal
colonoscopy result had a slightly elevated FC concentration (>50 µg/g), which was associated with the patients’ age and treatment with the above-mentioned drugs in the multivariate analysis.

Furthermore, wide daily variability of FC concentrations in stools has been observed [86]. Hence, this can be seen as a limitation for the FC application as a marker of the early response to induction therapy [87].

3.1.4. Technical Considerations

Currently, several commercial assays for FC measurement are available. Studies comparing the assays demonstrate similar performance when differentiating organic and functional bowel diseases [88]. Still, there are substantial inter-assay differences between FC tests from different manufacturers, hampering the establishment of a universal cutoff value [89]. New assays for simultaneous evaluation of FC and FIT (a latex agglutination turbidimetric immunoassay system) demonstrated similar performance to a standard ELISA assay [51].

Recently, a rapid test for FC evaluation using immunochromatographic methods has been developed as a point of care test (POCT). Although semiquantitative, rapid tests yield results in 30–40 min, allowing for an immediate adjustment of the therapy if needed. As such, they offer a useful alternative to ELISA, which is the gold standard for FC evaluation but is also time-consuming and requires laboratory infrastructure. The comparison of rapid tests with ELISA demonstrated a high level of agreement between both methods [90].

3.1.5. Other Fecal Markers

Among fecal markers other than calprotectin, the most intensively studied during the last decade were lactoferrin, another neutrophil-derived protein, which is responsible for limiting bacterial growth by lowering iron availability; matrix metalloproteinase (MMP)-9; and lipocalin-2. As an MH marker, lactoferrin and MMP-9 were more accurate in UC than in CD. In turn, lipocalin-2 was a more accurate marker of MH in CD (see Tables 4 and 5). However, the number of studies is limited and the conclusion regarding the potential utility of those markers in clinical practice cannot be drawn. Moreover, the properties of the aforementioned fecal markers were not shown to be superior to FC.
Table 4. Diagnostic performance of other fecal markers in MH detection for ulcerative colitis.

| Marker          | N MH/Total | MH Definition | ↑/↓ in Active Disease | Correlation with Endoscopic Score | Marker Performance | Authors              |
|-----------------|------------|---------------|-----------------------|----------------------------------|--------------------|---------------------|
|                 |            |               |                       |                                  | AUC                | Cutoff, Sens. and Spec. |
| MMP-9           | na/47      | MES < 1       | ↑                     | \( r = 0.653, p < 0.002 \)       | 0.9                | 2.38 ng/mL, 97% and 83% | Annahazi et al. [91] |
| MMP-9           | 9/32       | MES ≤ 1       | ↑                     | \( r = 0.58, p < 0.001 \)        | 0.87               | 900 ng/g, 80% and 91%  | Buisson et al. [92]  |
| MMP-9           | na/54      | MES ≤ 1       | ↑                     | \( r = 0.381, p = 0.021 \)       | 0.81               | 0.20 ng/mL, 75% and 96% | Farkas et al. [93]   |
| Lactoferrin     | 72/179 colonoscopies in 91 patients | RI ≤ 1 | ↑                     | \( r = 0.4, p < 0.001 \)         | 0.73               | 11.9 µg/g, 75% and 63%  | Langhorst et al. [53] |
| Lactoferrin     | 18/60      | UCEIS = 0     | ↑                     | \( r = 0.56, p < 0.00001 \)      | 0.71               | 78.3 ng/mL, 57% and 88% | Mine et al. [45]     |
| Lactoferrin     | na/20      | MES = 0       | ↑                     | \( r = 0.792, p < 0.01 \)        | 0.88               | 288.8 ng/mL, 69% and 100% | Sagawa et al. [94]   |
| Lipocalin-2     | 9/32       | MES ≤ 1       | ↑                     | ns                               | 0.68               | 6700 ng/g, 80% and 82%  | Buisson et al. [92]  |
| Lipocalin-2     | 265/370    | MES = 0       | ↑                     | na                               | 0.65               | 7 µg/g, 40% and 77%¹, 10 µg/g, 62% and 62%² | Magro et al. [95]    |
| Lipocalin-2     | UC: 15/43¹ | MES ≤ 1¹      | ↑                     | \( r = 0.82, p < 0.01¹ \)        | 0.86               | 2.2 mg/kg, 78% and 87%  | Thorsvik et al. [96] |
|                 | CD: 7/30²  | SES-CD ≤ 2²   | ↑                     | \( r = 0.58, p < 0.01² \)        |                    |                     |
| Neopterin       | 20/55      | RI ≤ 2        | ↑                     | \( r = 0.72, p < 0.001 \)        | 0.98               | 200 pmol/g, 100% and 74% | Nancey et al. [56]   |
| F-HNP           | 26/45      | MES ≤ 1       | ↑                     | \( r = 0.659, p < 0.001 \)       | 0.86               | 32 ng/mL, 96% and 74%  | Kanmura et al. [97]  |
| PMNE            | 72/179 colonoscopies in 91 patients | RI ≤ 1 | ↑                     | \( r = 0.38, p < 0.001 \)        | 0.7                | 0.035 µg/mL, 39% and 87% | Langhorst et al. [53] |

N, number of observations; MH, mucosal healing; ↑/↓, increased/decreased; r, correlation coefficient; p, p-value; UC, ulcerative colitis; CD, Crohn’s disease; MES, Mayo Endoscopic Subscore; UCEIS, Ulcerative Colitis Endoscopic Index of Severity; RI, Rachmilewitz Index; SES-CD, Simple Endoscopic Score for Crohn’s Disease; MMP-9, matrix metalloproteinase 9; F-HNP, fecal human neutrophil peptides; PMNE, polymorphonuclear neutrophil elastase; FIT, fecal immunochemical test; AUC, area under receiver operating characteristics (ROC) curve; Sens., sensitivity; Spec., specificity; na, not available; ns, not significant. Numbers in superscript indicate parameters corresponding with a given cohort or selected cutoff.
Table 5. Diagnostic performance of other fecal markers in MH detection for Crohn’s disease.

| Marker      | N MH/Total | MH Definition | ↑/↓ in Active Disease | Correlation with Endoscopic Score | Marker Performance | Authors     |
|-------------|------------|---------------|-----------------------|----------------------------------|--------------------|-------------|
|             |            |               |                       |                                  | AUC               | Cutoff      | Sens. and Spec. |            |
| MMP-9       | 31/54      | CDEIS no ulceration | ↑                     | \( r = 0.55, \ p < 0.001 \)    | 0.72               | 350 ng/g | 64% and 90% | Buisson et al. [92] |
| MMP-9       | na/50      | SES-CD ≤ 4    | ↑                     | \( r = 0.5, \ p < 0.0001 \)     | 0.68               | 145.82 µg/mL | 85% and 61% | Farkas et al. [93] |
| Lactoferrin | na/101     | SES-CD ≤ 3    | ↑                     | \( r = 0.5, \ p < 0.0001 \)     | 0.68               | 145.82 µg/mL | 85% and 61% | Klimczak et al. [98] |
| Lipocalin-2 | 31/54      | CDEIS no ulceration | ↑                     | \( r = 0.49, \ p < 0.001 \)    | 0.68               | 67000 ng/g | 46% and 86% | Buisson et al. [92] |
| Neopterin   | 40/78      | SES-CD ≤ 2    | ↑                     | \( r = 0.47, \ p < 0.001 \)    | 0.75               | 200 pmol/g | 73% and 74% | Nancy et al. [56] |

N, number of observations; MH, mucosal healing; ↑/↓, increased/decreased; r, correlation coefficient; \( p \)-value; SES-CD, Simple Endoscopic Score for Crohn’s Disease; CDEIS, Crohn’s Disease Endoscopic Index of Severity; MMP-9, matrix metalloproteinase 9; AUC, area under receiver operating characteristics (ROC) curve; Sens., sensitivity; Spec., specificity; na, not available; ns, not significant.
3.2. Interpretative Synthesis of Data: Serum-Based Markers

3.2.1. C-Reactive Protein (CRP)

The most intensively evaluated serum-based marker was CRP, examined in 30 eligible publications, which was frequently done as a reference for novel potential markers. CRP positively correlated with the endoscopic activity of the disease, yielding correlation coefficients from 0.29 to 0.63 for UC (Table 6) and from 0.31 to 0.71 for CD (Table 7). Reported areas under the receiver operating characteristics (ROC) curves (AUCs), allowing for the evaluation of the overall accuracy of a marker independently from the selected cut-off, ranged from fair to very good overall accuracy for both UC (0.60–0.96) and CD (0.64–0.92) (Tables 6 and 7, respectively).

### Table 6. Diagnostic performance of C-reactive protein in MH detection for ulcerative colitis.

| N MH/Total | MH Definition | Correlation with Endoscopic Score | Marker Performance | Authors |
|------------|---------------|-----------------------------------|--------------------|---------|
|            |               |                                   | AUC                | Cutoff  | Sens. and Spec. |       |
| 47/79\(^1\) | MES = 0\(^1\) | r = 0.61, p < 0.05                | 0.72\(^1\)        | 0.05 mg/dL\(^1\) | 71% and 71%\(^1\) | Arai et al. \[74\] |
| 66/79\(^2\) | MES ≤ 1\(^1\) |                                   | 0.96\(^2\)        | 0.39 mg/dL\(^2\) | 92% and 92%\(^2\) |       |
| 20/43      | EAI ≤ 3       | na                                | 0.80              | 3.8 mg/L     | 90% and 67% | Beyazit et al. \[99\] |
| 6/34       | MES = 0       | r = 0.35, p = 0.07                | na                | 5 mg/L       | 65% and 50% | Bodeier et al. \[81\] |
| 12/19 (CR)\(^3\) | MES ≤ 2 | r = 0.634, p < 0.001             | 0.86\(^3\)        | 5 mg/L       | 100% and 23%\(^3\) | Chen et al. \[47\] |
| 12/45 (all)\(^2\) | MES ≤ 1 | r = 0.372, p < 0.013             | 0.701             | 5 mg/L\(^1\) | na and 82%\(^1\) | de Bruyn et al. \[100\] |
| 28/66 (NT)\(^1\) | MES ≤ 1 | r = 0.317, p < 0.011             | 0.802             | 7.2 mg/L\(^1\) | 44% and 93%\(^2\) |       |
| 88/132 (T)\(^1\) | MES ≤ 1 | r = 0.408, p < 0.012             | 0.773             | 7.3 mg/L\(^1\) | 39% and 91%\(^3\) |       |
| 48/103     | MES ≤ 1 | r = 0.326, p = 0.001             | 0.60              | 0.7 mg/L     | 52% and 69% | Dranga et al. \[101\] |
| 29/44      | MES ≤ 1 | na                                | 0.77              | 28 mg/L      | 71% and 85% | Hassan et al. \[102\] |
| 10/85      | MES = 0 | r = 0.386, p < 0.001             | na                | 0.5 mg/dL    | 33% and 100% | Jung et al. \[103\] |
| 30/48      | MES = 0 | ns                                | 0.7               | 0.25 mg/dL   | 81% and 53% | Jusse et al. \[32\] |
| 72/179     | RI ≤ 1 | r = 0.29, p < 0.001              | 0.65              | 0.25 mg/dL   | 46% and 82% | Langhorst et al. \[53\] |
| 16/53      | MES = 0 | r = 0.46, p < 0.001              | 0.673             | 0.5 mg/L     | 54% and 83% | Neubauer et al. \[104\] |
| 82/149     | MES = 0\(^1\) | na                                | 0.621             | 1.6 mg/L\(^1\) | 58% and 66%\(^1\) | Rosenberg et al. \[105\] |
| 7/32       | MES ≤ 1 | r = 0.387, p < 0.05              | 0.77              | na           | na           | Samant et al. \[106\] |
| 34/134     | RI ≤ 3 | r = 0.503, p < 0.001             | na                | 5 mg/L       | 67% and 60% | Schoepfer et al. \[30\] |
| 54/228     | mBS ≤ 1 | r = 0.556, p < 0.001             | 0.78              | 6 mg/L       | 72% and 68% | Schoepfer et al. \[58\] |
| 16/129\(^1\) | 50/129\(^2\) | Matsu = 1\(^1\)  Matsu ≤ 2\(^2\) | 0.671             | 0.812        | na           | na           | Shinzaki et al. \[107\] |
| 9/34 (na)* | MES = 0 | na                                | 0.71              | 0.4 mg/L     | 71% and 30% | Tran et al. \[108\] |
| 52/207     | mMES ≤ 1\(^1\) | cmES ≤ 8\(^2\) | r = 0.38, p < 0.05\(^4\) | 0.751        | 0.23 mg/dL\(^1\) | 81% and 57%\(^1\) | Uchihara et al. \[109\] |
| 94/105 (CR) | MES = 0\(^1\) | na                                | 0.621             | 0.08 mg/dL\(^1\) | na           | Yamaguchi et al. \[65\] |
| na/65      | mBS = 0 | r = 0.45, p < 0.001              | 0.68              | 5 mg/L       | 80% and 50% | Falvey et al. \[59\] |
| 722 endoscopies in 552 patients | P-T = 0\(^1\) | na                                | 0.761             | 0.05 mg/dL\(^1\) | 51% and 85%\(^1\) |       |
|            | MES ≤ 1\(^1\) | r = 0.503, p < 0.001\(^2\) | 0.722             | 8 mg/L\(^2\) | 53% and 84%\(^2\) |       |
|            | mBS = 0 | r = 0.520, p < 0.001\(^3\) | 0.783             | 8 mg/L\(^3\) | 52% and 87%\(^3\) |       |
|            | HSI ≤ 4\(^4\) | r = 0.507, p < 0.001\(^4\) | 0.774             | 8 mg/L\(^4\) | 51% and 85%\(^4\) |       |
|            | RI ≤ 4\(^5\) | r = 0.523, p < 0.001\(^5\) | 0.765             | 8 mg/L\(^5\) | 51% and 87%\(^5\) |       |

N, number of observations; MH, mucosal healing; r, correlation coefficient; p, p-value; CR, subgroup of patients in clinical remission; NT, not treated with infliximab; T, treated with infliximab; MES, Mayo Endoscopic Subscore; UCEIS, Ulcerative Colitis Endoscopic Index of Severity; RI, Rachmilewitz Index; mBS, modified Baron Score; EAI, Endoscopic Activity Index; P-T, Powell-Tuck Assessment; HSI, Hanauer’s Sigmoidoscopic Index; AUC, area under receiver operating characteristics (ROC) curve; Sens., sensitivity; Spec., specificity; na, not available; ns, not significant; *, counted from a scatter-plot. Numbers in superscript indicate parameters corresponding with a given MH definition or cohort.
Table 7. Diagnostic performance of C-reactive protein in MH detection for Crohn’s disease.

| N        | MH/Total            | MH Definition | Correlation with Endoscopic Score | Marker Performance | Authors                  |
|----------|---------------------|---------------|-----------------------------------|--------------------|--------------------------|
| 42/209   | SES-CD ≤ 2         | r = 0.56, p < 0.001 | 0.64 3 mg/L 50% and 24%          | Björkesten et al. [26] |
| 31/50    | SES-CD ≤ 3         | r = 0.45, p = 0.07 | na 5 mg/L 65% and 56%            | Bodelier et al. [81] |
| 20/34    | SES-CD ≤ 3         | r = 0.658, p < 0.01 | 0.761 5 mg/L 83% and 46%        | Chen et al. [47]   |
| 21/56 (all) | SES-CD ≤ 3   | r = 0.658, p < 0.01 | 0.812 5 mg/L 91% and 71%       |
| 38/108   | Descriptive corresponding with SES-CD ≤ 2 | r = 0.307, p < 0.001 | 0.74 5 mg/L 79% and 57%          | de Bruyn et al. [111] |
| na/107   | SES-CD ≤ 2         | r = 0.44, p < 0.001 | 0.64 5 mg/L 67% and 60%          | Falvey et al. [59] |
| na/33    | SES-CD = 0         | r = 0.709, p < 0.001 | 0.92 0.03 mg/dL 86% and 89%      | Hosomi et al. [112] |
| 19/55    | SES-CD ≤ 3         | r = 0.61, p < 0.01 | 0.75 0.11 mg/dL 68% and 78%      | Ishihara et al. [113] |
| 6/34     | SES-CD ≤ 3         | r = 0.585, p < 0.001 | na 0.4 mg/dL 89% and 67%         | Jung et al. [104] |
| 4/55     | CDEIS ≤ 2          | r = 0.672, p < 0.001 | na 3 mg/L 80% and 76%            | Karczewski et al. [78] |
| 11/43    | Descriptive corresponding with SES-CD ≤ 3 | na                | 0.78 1.1 mg/L 100% and 38%       | Miranda-Garcia et al. [114] |
| 51/136   | SES-CD ≤ 3         | r = 0.458, p < 0.001 | 0.69 5 mg/L 84% and 53%          | Schaeffer et al. [77] |
| 26/140   | SES-CD ≤ 3         | r = 0.53, p < 0.01 | na 5 mg/L 58% and 68%            | Schoepfer et al. [30] |
| 39/94    | Descriptive corresponding with SES-CD ≤ 2 | na                | 0.75 4 mg/L 69% and 62%          | Yarur et al. [115] |

\(N\), number of observations; \(MH\), mucosal healing; \(r\), correlation coefficient; \(p\), \(p\)-value; \(CR\), subgroup of patients in clinical remission; \(SES-CD\), Simple Endoscopic Score for Crohn’s Disease; \(CDEIS\), Crohn’s Disease Endoscopic Index of Severity; \(MH\), mucosal healing; \(AUC\), area under receiver operating characteristics (ROC) curve; \(Sens.\), sensitivity; \(Spec.\), specificity; \(na\), not applicable. Numbers in superscript indicate parameters corresponding with a given cohort.
There was a very large variation in the selected optimal cut-off values, ranging from 0.4 to 28 mg/L. Differences of two orders of magnitude are unlikely for a standardized marker, such as CRP, and might imply errors in the reported units of concentration. The analysis of CRP performance as the MH marker revealed that it displayed better sensitivity than the specificity for CD, with respective median values of 79.5% against 61%, but better specificity than sensitivity for UC, with respective median values of 82% against 66%. For UC, CRP performed better when mucosal healing was defined as MES ≤ 1, or equivalent, than when restricted to MES = 0. Rosenberg et al. [106], Arai et al. [74], and Shinzaki et al. [108] compared the diagnostic power of CRP using both MH definitions. They showed CRP performance to be superior in terms of sensitivity, specificity, and/or the overall accuracy in the case of the less restrictive definition. Chen et al. [47], in turn, compared CRP as the MH marker in a cohort consisting exclusively of selected patients in clinical remission with a cohort of UC patients with clinically active or inactive disease, finding the marker’s performance to be superior in terms of specificity in the latter cohort. Accordingly, some authors have demonstrated that CRP was better at detecting moderate-to-severe disease activity but failed to differentiate between inactivity and mild endoscopic activity [30,31,78,103,105,107]. As demonstrated by Yoon et al. [110], CRP displayed similar accuracy, sensitivity, and specificity as the MH marker regardless of the type of score used for MH evaluation. However, it has to be mentioned that some authors failed to observe a significant association between CRP and endoscopic scores [32,112–118] and/or did not find CRP to be significantly superior to a chance marker in detecting MH in UC [42,114,119] or CD [32].

3.2.2. Other Acute Phase Reactants (APRs)

CRP was not the only acute phase reactant (APR) that has been evaluated in terms of its association with the endoscopic activity of IBD. During the last decade, other positive APRs, such as procalcitonin, fibrinogen, orosomucoid, and serum amyloid A, as well as negative APRs, such as albumin and transferrin, have been appraised in this respect, although less extensively than CRP and with less success. Procalcitonin (PCT) increases in response to pro-inflammatory stimuli, particularly of bacterial origin, where the sensitivity and specificity of which as a bacterial infection marker is claimed to be superior to CRP. Accordingly, in acute UC (UCEIS ≥ 3), PCT concentrations reflected endoscopic activity more precisely than those of CRP and albumin (respectively, \( r = 0.46, r = 0.18, \) and \( r = -0.23 \)), as reported by Wu et. al. [120], and contrary to CRP, differed significantly between MES = 2 and MES = 3, as demonstrated by Koido et al. [121]. Unfortunately, none of the authors evaluated the diagnostic power of procalcitonin as a potential MH marker. Moreover, others failed to confirm a significant association between procalcitonin and the endoscopic activity of UC [47,112,122] or CD [47,112]. Zezos et al. [123] showed that fibrinogen concentration positively correlates with endoscopic scores to a similar extent as CRP in UC (\( r = 0.49, p < 0.001 \) for both) and Eder et al. [124] in CD (respectively, \( r = 0.59 \) and \( r = 0.57, p < 0.0001 \) for both); however, these were not followed by the evaluation of its diagnostic power. As reported by Miranda-Garcia et al. [114], fibrinogen, with an AUC < 0.05, failed to detect MH in UC patients (Table 8) but it displayed a good overall accuracy as an MH marker, accompanied by an excellent sensitivity in one study on CD patients (Table 9). In the same study investigating fibrinogen, orosomucoid was evaluated and yielded similar overall accuracy and sensitivity but slightly lower specificity in CD, but also failed as an MH marker for UC [114]. Its unsuitability for MH detection in UC has been confirmed by Carlsten et al. [42]. Furthermore, in CD, serum amyloid A (SAA) was found to display identical good overall accuracy in two studies but superior sensitivity in one [115] and superior specificity in the other [123], probably owing to the different cutoff values applied (Table 9). For UC, SAA accuracy was found to be insufficient [42]. Albumin displayed a good overall accuracy as an MH marker for the general UC population in a study of Uchihara et al. [109] but not those of Carlsten et al. [42] or Jusué et al. [32]. For CD, albumin has been reported to inversely correlate with the SES-CD score (\( r = -0.62, p < 0.0001 \)) [124] but others have found it to fail as an MH marker [32]. Moreover, even if significantly better than a chance marker, albumin seems to share similar drawbacks to CRP, i.e., being less efficient in detecting MH among patients with clinical remission [65] (Table 8). Concerning
transferrin, only its correlation with MES was reported ($r = -0.37, p = 0.001$) [125]. Uchihara et al. [109] argued that the unsatisfactory performance of APRs in differentiating mucosal inflammation from healing results from the fact that during endoscopy, only fragments of mucosa with the most severe inflammation are considered when reporting activity scores. To support their thesis, the authors compared CRP and albumin (Table 6) and albumin (Table 8) performance as the MH markers using the traditional MES score and cumulative MES score, in which scores obtained for six different bowel regions were added. Indeed, both CRP and albumin displayed superior AUCs and specificities when the MH definition was based on the cumulative MES score.

Table 8. Diagnostic performance of other serum-based markers in MH detection for ulcerative colitis.

| Marker       | N MH/Total | MH Definition | $t$ in Active Disease | Correlation with Endoscopic Score | Marker Performance | Authors                  |
|--------------|------------|---------------|-----------------------|-----------------------------------|--------------------|--------------------------|
|              |            |               |                       |                                   |                    |                          |
| VEGF-A       | 16/37      | MES = 0       | $r = 0.397, p = 0.013$ | 0.72 341 ng/mL 64% and 88%        | AUC 0.927          | Trejo-Vasquez et al. [133]|
| ADA          | 28/43      | EA1 ≤ 3       | na                    | 0.87 9.45 U/L 84% and 83%         | AUC 0.901          | Beyazit et al. [79]      |
| ST2          | 25/83      | EA1 ≤ 4       | na                    | 0.81 47.1 pg/mL 72% and 72%       | AUC 0.910          | Böger et al. [127]       |
| ST2          | 44/84      | MES ≤ 1       | $r = 0.762, p < 0.001$ | 0.92 74.8 ng/mL 83% and 83%       | AUC 0.901          | Díaz Jiménez et al. [128]|
| ST2          | 18/24      | MES ≤ 1       | $r = 0.66, p < 0.001$  | na 74.8 ng/mL 44% and 95%         | AUC 0.901          | Díaz Jiménez et al. [129]|
| NGAL         | 14/41      | MES ≤ 1       | $r = 0.574, p < 0.05$  | 0.76 43.6 ng/mL 96% and 94%       | AUC 0.910          | Budzyńska et al. [130]   |
| NGAL-26/66   | 88/123     | MES ≤ 1       | $r = 0.317, p < 0.011$ | 0.793 97.7 ng/mL 43% and 93%      | AUC 0.910          | de Bruijn et al. [100]   |
| MMP9 complex | 80/123     | MES ≤ 1       | $r = 0.37, p < 0.011$  | 0.783 93.2 ng/mL 44% and 91%      | AUC 0.910          | Neubauer et al. [104]    |
| sIL2R        | na/58     | MES = 0       | $r = 0.357, p < 0.02$  | 0.65 274 U/mL 60% and 76%        | AUC 0.927          | Hosomi et al. [112]      |
| sTREM-1      | 10/59      | MES = 0       | $r = 0.498, p < 0.01$  | na 60 pg/mL 59% and 80%           | AUC 0.927          | Jung et al. [103]        |
| IL-6         | 5/45       | MES = 0       | $r = 0.596, p < 0.01$  | 0.93 9.6 pg/mL 80% and 95%        | AUC 0.927          | Mankowska-Wierzbicka et al. [116]|
| IL-17        | 5/45       | MES = 0       | $r = 0.578, p < 0.01$  | 0.93 6.6 pg/mL 60% and 92%        | AUC 0.927          | Mankowska-Wierzbicka et al. [114]|
| TNFa         | 5/45       | MES = 0       | $r = 0.701, p < 0.01$  | 0.98 7.6 pg/mL 80% and 99%        | AUC 0.927          | Mankowska-Wierzbicka et al. [114]|
| IL-9         | na/53      | MES = 0       | $r = 0.74, p < 0.01$   | 0.97 20.5 pg/mL 94% and 92%       | AUC 0.927          | Matusiewicz et al. [119] |
| GM-CSF       | 16/53      | MES = 0       | $r = 0.56, p < 0.01$   | 0.91 16.7 pg/mL 69% and 97%       | AUC 0.927          | Neubauer et al. [104]    |
| IFNγ         | 16/53      | MES = 0       | $r = 0.55, p < 0.01$   | 0.78 83.2 pg/mL 100% and 65%      | AUC 0.927          | Neubauer et al. [104]    |
| IL-12p70     | 16/53      | MES = 0       | $r = 0.49, p < 0.01$   | 0.71 21.6 pg/mL 50% and 100%      | AUC 0.927          | Neubauer et al. [104]    |
| Nampt        | 66/98      | MES ≤ 1       | $r = 0.47, p < 0.01$   | 0.77 1.54 pg/mL 76% and 75%       | AUC 0.927          | Neubauer et al. [131]    |
| LRG          | 22/67      | RS ≤ 1        | na                    | na 13.74 pg/mL 69% and 55%        | AUC 0.927          | Rodriguez-Peralvarez et al. [132]|
| TTF3         | 43/167     | RS ≤ 1        | na                    | 0.73 1.27 mg/mL 70% and 68%       | AUC 0.927          | Srivastava et al. [133]  |
| TTF3         | 50/116     | UCEIS = 0 and MES = 0 | $r = 0.82 for UCEIS, p < 0.001 | 0.927 6.74 ng/mL 89% and 86% | AUC 0.927          | Nakov et al. [66]        |
| L1-37        | 9/34 (na)* | MES = 0       | na                    | 0.76 32 mg/mL 100% and 38%        | AUC 0.927          | Tran et al. [108]        |
| Leptin       | 8/23 UC    | MES = 0       | na                    | na 2.5 mg/mL 88% and 45%          | AUC 0.927          | Trojo-Vazquez et al. [134]|
| ALB          | 52/207     | mMES ≤ 1      | $r = -0.52, p < 0.05$  | 0.802 4.2 g/dl 73% and 72%        | AUC 0.927          | Uchihara et al. [109]    |
| ALB          | 94/105     | MES = 0       | $r = 0.56, p < 0.05$   | 0.802 4.3 g/dl 73% and 72%        | AUC 0.927          | Yamaguchi et al. [65]    |

$N$, number of observations; MH, mucosal healing; $t$, increased/decreased; $r$, correlation coefficient; $p$, $p$-value; CR, subgroup of patients in clinical remission; NT, not treated with infliximab; T, treated with infliximab; (m)MES, Mayo Endoscopic Subscore; c(MES), cumulative Mayo Endoscopic Score; UCEIS, Ulcerative Colitis Endoscopic Index of Severity; RI, Rachmilewitz Index; EAI, Endoscopic Activity Index; SES-CD, Simple Endoscopic Score for Crohn’s Disease; VEGF-A, vascular endothelial growth factor-A; ADA, adenosine deaminase; ST2, decoy receptor for IL-33 (member of IL-1 receptor family); NGAL, neutrophil gelatinase B–associated lipocalin; NGAL-MMP9, neutrophil gelatinase B–associated lipocalin-matrix metalloproteinase 9; IL-6, interleukin-6; TNFα, tumor necrosis factor α; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFNγ, interferon-γ; Nampt, nicotinamide phosphoribosyltransferase; LRG, leucine-rich alpha-2-glycoprotein; TTF3, trefoil factor-3; L1-37, cathelicidin; ALB, albumin; AUC, area under receiver operating characteristics (ROC) curve; Sens., sensitivity; Spec., specificity; na, not available; *, counted from a scatterplot. Numbers in superscript indicate parameters corresponding with a given MH definition or cohort.
3.2.3. Cytokines, Their Receptors, and Growth Factors

CRP and other positive APRs are produced in response to cytokines, mainly interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α, which also affect the concentrations of negative APRs [135]. Unsurprisingly, those cytokines, as well as many others, have also been of interest as potential MH markers, especially given that the imbalance between pro- and anti-inflammatory cytokines is a hallmark of IBD [136]. For UC, TNFα and IL-9 displayed an excellent overall accuracy, IL-6 and IL-17A displayed very good accuracy, granulocyte-macrophage colony-stimulating factor (GM-CSF) and interferon (IFN)γ displayed good accuracy, and soluble IL2 receptor (sIL2R) and IL-12(p70) displayed fair accuracy. Most of those cytokines had higher specificities than sensitivities (Table 8). However, TNFα, IL-6, IL17, and IFNγ in Rodriguez–Peralvarez et al.’s [132] study failed to detect MH and the only cytokine better than a chance marker was IL-8, displaying only a fair accuracy. IL-6 displayed an excellent overall accuracy as an MH marker for CD, IL-9 and IL-1β displayed good accuracy, and sIL2R displayed fair accuracy. The AUC for IL-17 was not calculated but the cytokine displayed good sensitivity and specificity (Table 9). While some authors reported significant correlations between the endoscopic activity of CD and IL-1, IL-6, IL-12, IFNγ, and TNFα (all r > 0.9, p < 0.0001) [137], others failed to observe significant associations for IL-6, TNFα, and IFNγ [78]. Algaba et al. [126] evaluated a panel of angiogenic factors as potential markers differentiating mucosal inflammation from healing, of which, only vascular endothelial growth factor (VEGF)-A for UC (Table 8) and angiopoietin-1 for CD (Table 9) performed significantly better than a chance marker, displaying fair overall accuracy and better sensitivities than specificities. Good and very good accuracies were reported for ST2 (interleukin 1 receptor-like 1) by two research groups for UC (Table 8) and fair accuracy by one group for CD (Table 9).
Table 9. Diagnostic performance of other serum-based markers in MH detection in Crohn’s disease.

| Marker                  | N MH/Total | MH Definition | ↑/↓ in Active Disease | Correlation with Endoscopic Score | Marker Performance | Authors                  |
|-------------------------|------------|---------------|-----------------------|-----------------------------------|-------------------|--------------------------|
| Ang1                    | 19/35      | SES-CD ≤ 2    | ↑                     | r = 0.362, p = 0.049              | 0.65              | 47.8 ng/mL 52% and 67%  | Algaba et al. [126]     |
| ST2                     | 52/8       | SES-CD ≤ 2    | ↑                     | na                                | 0.73              | 57.6 pg/mL 100% and 56% | Boga et al. [127]       |
| NGAL                    | 45/79      | SES-CD ≤ 7    | ↑                     | r = 0.296, p < 0.001              | 0.77              | 72.5 ng/mL 48% and 83%  | Budzynska et al. [130]  |
| NGAL-MMP9 complex       | 38/108     | Descriptive   | ↑                     | r = 0.296, p < 0.001              | 0.77              | 45 ng/mL 82% and 60%    | de Bruyn et al. [111]   |
| IL-9                    | 23/50      | Descriptive   | ↑                     | r = 0.395, p < 0.001              | 0.78              | 18.1 pg/mL 52% and 100% | Feng et al. [138]       |
| sIL2R                   | na/33      | SES-CD = 0    | ↑                     | r = 0.516, p = 0.002              | 0.74              | 283 U/mL 71% and 73%    | Hosomi et al. [112]     |
| sCD14-ST                | na/33      | SES-CD = 0    | ↑                     | r = 0.512, p = 0.002              | 0.85              | 89 pg/mL 86% and 85%    | Hosomi et al. [112]     |
| SAA                     | 19/55      | SES-CD ≤ 3    | ↑                     | r = 0.64, p < 0.01                | 0.77              | 5.9 µg/dL (mL)* 68% and 83% | Ishihara et al. [113] |
| SAA                     | 39/94      | Descriptive   | ↑                     | na                                | 0.77              | 28 mg/L 95% and 64%     | Yarur et al. [115]      |
| sTREM-1                 | 6/34       | SES-CD ≤ 3    | ↑                     | na                                | Na                | 60 pg/mL 29% and 83%    | Jung et al. [103]       |
| IL-17                   | 4/55       | CDEIS ≤ 2     | ↑                     | r = 0.296, p < 0.005              | Na                | 7.05 pg/mL 80% and 74% | Karczewski et al. [78]  |
| ERβ/ERα                 | 11/31      | SES-CD ≤ 2    | ↑                     | Na                                | Na                | 0.85 (ratio) 91% and 70% | Linares et al. [139]    |
| IL-6                    | 6/32       | CDEIS ≤ 7     | ↑                     | r = 0.957, p < 0.001              | 1.00              | 15.9 pg/mL 100% and 100% | Ljuca et al. [137]      |
| Orosomucoid             | 11/43      | Descriptive   | ↑                     | na                                | 0.85              | 119.5 mg/dL 100% and 57% | Miranda-García et al. [114] |
| Fibrinogen              | 11/43      | Descriptive   | ↑                     | na                                | Na                | 817 mg/dL 100% and 65% | Miranda-García et al. [114] |
| Ficolin-2               | 51/136     | SES-CD ≤ 3    | ↑                     | r = 0.171, p = 0.047              | 0.61              | 2.404 µg/mL 51% and 68% | Schaffer et al. [87]    |
| IL-1β                   | 25/47 (RP) | Descriptive   | ↑                     | na                                | Na                | Na                        | Yarur et al. [140]      |
Table 9. Cont.

| Marker | N MH/Total | MH Definition | ↑/↓ in Active Disease | Correlation with Endoscopic Score | Marker Performance | Authors |
|--------|------------|---------------|-----------------------|-----------------------------------|-------------------|---------|
|        |            |               |                       |                                   | AUC Cutoff Sens. and Spec. |         |
| ICAM   | 25/47 (RP) | Descriptive corresponding with SES-CD ≤ 2 | ↑ | na | 0.89 | na | na | Yarur et al. [140] |

N, number of observations; MH, mucosal healing; ↑/↓, increased/decreased; r, correlation coefficient; p, p-value; RP, patients resistant to anti-TNF treatment; SES-CD, Simple Endoscopic Score for Crohn’s Disease; CDEIS, Crohn’s Disease Endoscopic Index of Severity; Ang1, angiopoietin 1; ST2, decoy receptor for IL-33 (a member of the IL-1 receptor family); NGAL, neutrophil gelatinase B–associated lipocalin; NGAL-MMP9, neutrophil gelatinase B–associated lipocalin-matrix metalloproteinase 9; IL, interleukin; sIL2R, soluble IL-2 receptor; sCD14-ST, soluble CD14 subtype (presepsin); SAA, serum amyloid A; sTREM-1, soluble triggering receptor expressed on myeloid cells-1; ERβ/ERα, ratio of circulating estrogen receptors beta and alpha; ICAM, intercellular adhesion molecule 1; AUC, area under receiver operating characteristics (ROC) curve; Sens., sensitivity; Spec., specificity; na, not available; ns, not significant; * different units stated throughout the article.
3.2.4. Other Serum-Based Markers

Most of the remaining serum-based markers evaluated during the last decade as potential MH markers are also associated with inflammatory and immune responses. Several authors have evaluated lipocalin-2 (neutrophil gelatinase-associated lipocalin (NGAL)), a glycoprotein that is physiologically present in serum at low concentrations but over-secreted in response to stimuli associated with epithelial damage, either alone or in a complex with matrix metalloproteinase 9 (MMP9). NGAL displayed good overall accuracy for UC (Table 8) and fair to good accuracy for CD (Table 9). Trifoliate factor (TTF)-3, a protein involved in healing of the epithelium, protecting the mucosa from insults, and the stabilization of the mucus layer, positively correlated with UCEIS [141] and displayed a fair overall accuracy as an MH marker for UC (Table 8), but failed to reflect endoscopic activity [141] or indicate MH for CD [124].

In UC, individual studies have been dedicated to adenosine deaminase activity, a non-specific marker of T-cell activation, antimicrobial peptide LL-37, adipokine and immunomodulatory cytokine visfatin (Namp), and lysine-rich α2 glycoprotein (LRG), a protein involved in inflammatory responses to bacterial infections as well as in angiogenesis; all of these have been characterized by good overall accuracy, sensitivity, and specificity (Table 8).

While visfatin performed well for UC patients, it failed to detect MH in a mixed cohort of UC and CD patients examined by Trejo-Vasquez et al. [134]. The authors analyzed a diabetic panel including, among others, plasminogen activator inhibitor (PAI)-1 and adipokines (leptin, resistin, and visfatin), of which, only leptin displayed a fair overall accuracy as an MH marker (Table 8). Jung et al. [103] evaluated a soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in both UC and CD and found the marker to display fair sensitivity and good specificity for UC (Table 8), but with an estimated 29% sensitivity, it failed as an MH marker for CD. TREM-1 belongs to the immunoglobulin superfamily and is present on monocytes, neutrophils, macrophages, and endothelial cells, and its soluble form accompanies inflammatory and infectious conditions. Presepsin (a soluble cluster-of-differentiation 14 subtype (sCD14-ST)) is a truncated form of the co-receptor for toll-like receptor 4 (TLR4), which is expressed on phagocytic cells and shed into the circulation upon lipopolysaccharide binding in a manner proportional to the severity of the inflammatory response. Although correlated with endoscopic scores for both CD and UC ($r = 0.277$, $p = 0.022$ for UC), presepsin, in turn, differentiated mucosal inflammation and healing only for CD patients with good accuracy, sensitivity, and specificity (Table 9). Moreover, Hosomi et al. [112] demonstrated that the combined evaluation of presepsin with CRP substantially improves the sensitivity (100%) compared to individual assessments of CRP and presepsin. Similarly, regarding presepsin, the ratio of estrogen receptors (ER) β-to-α was a good MH indicator in CD (Table 9) but not UC. Solely for CD, ficolin-2, a liver-synthesized pattern recognition molecule involved in inflammation and immunity, was examined. Unlike most of the evaluated markers, its concentrations had already significantly increased in mild mucosal inflammation without a further elevation in moderate and severe inflammation, potentially making it a unique tool for differentiating mild inflammation from complete healing [77]. However, the reported overall accuracy and sensitivity have only been fair and the specificity of ficolin-2 was rather poor (Table 9).

Yarur et al. [115,140] examined the performance of adhesion molecules and key proinflammatory cytokines, namely V-CAM, I-CAM, IL-1β, IL-6, IL-8, and TNFα, as potential MH markers in CD. They found that each marker’s performance in a general population of CD patients was unsatisfactory. However, as a panel, they achieved good overall accuracy ($AUC = 0.81$) [115]. Moreover, IL-1β and I-CAM were good predictors of MH in a subpopulation of CD patients resistant to anti-TNFα therapy [140].

3.3. Interpretative Synthesis of Data: Urine-Based Markers

The only eligible study evaluating potential MH markers in urine was that of Arai et al. [142], who examined prostaglandin E and found it to be a good or even excellent marker, depending on the MH definition, which showed a stepwise increase along with MES (Table 10).
Table 10. Diagnostic performance of urine-based markers in MH detection for ulcerative colitis.

| Marker | N MH/Total | MH Definition | ↑/↓ in Active Disease | Correlation with Endoscopic Score | Marker Performance | Authors |
|--------|------------|---------------|-----------------------|-----------------------------------|--------------------|---------|
|        |            |               |                       |                                   |                    |         |
| PGE    | 47/79\(^1\) | MES = 0\(^1\) | ↑                     | \(r = 0.85, p < 0.05\)           | 0.90\(^1\)         | Arai et al. [142] |
|        | 66/79\(^2\) | MES ≤ 1\(^2\) |                       |                                   | 0.98\(^2\)         |         |

\(N\), number of observations; MH, mucosal healing; \(↑/↓\), increased/decreased; \(r\), correlation coefficient; \(p\), \(p\)-value; PGE, prostaglandin E; CR, creatinine; MES, Mayo Endoscopic Score; AUC, area under receiver operating characteristics (ROC) curve; Sens., sensitivity; Spec., specificity. Numbers in superscript indicate parameters corresponding with a given MH definition.
4. Review Limitations

Although all possible efforts were made to make the review complete, some potentially relevant publications could be overlooked due to the huge number of records to be screened at the stage of the title and abstract selection. Moreover, several studies reporting marker performance were excluded upon a full-text reading due to a lack of clarity concerning whether clinical or endoscopic remission was evaluated. Furthermore, it must be pointed out that most studies included in the final analysis were conducted on small cohorts and/or had an unbalanced design with a substantial disparity between patients with endoscopic remission and inflammation, and thus the reported accuracies, sensitivities, and specificities ought to be interpreted with caution.

5. Conclusions

At the beginning of the 21st century, we are facing a growing incidence of IBD, especially in regions where the previously reported incidence was low, i.e., in Asia and Eastern Europe [143]. The complex nature of these diseases makes IBD patients a heterogeneous group of subjects, which can benefit from an individualized approach [144]. Still, available diagnostic and therapeutic possibilities are limited. MH has recently received interest as a therapeutic goal, for the evaluation of which, endoscopy is mandatory. At the time being, biochemical biomarkers, although possessing many advantages, cannot substitute for an invasive, expensive, and time-consuming colonoscopy. Out of those used in clinical practice, fecal calprotectin remains the closest to “the perfect” MH marker. However, as long as the standardized cutoff value of FC is missing, it cannot be broadly applied as the surrogate marker of endoscopic remission. Other fecal or serum-based markers also seem to be promising. However, as they were not evaluated in replicated and cross-validated studies and were often conducted on small cohorts, further research is required before they could substitute or be used alongside fecal calprotectin.

Ongoing research on novel biochemical biomarkers of MH should focus on validation of the most promising indices in larger and better-defined cohorts. As indicated by this review, interleukins upstream of CRP in an inflammatory cascade, namely IL-1β and IL-6, have the greatest diagnostic potential for colonic CD. For UC, IL-6, as well as TTF3, IL-9, ST2, TNFα, and ADA, seem to be more powerful than other markers. A promising tactic for getting the most out of biochemical biomarkers would be to combine multiple markers into panels, especially these displaying a high sensitivity but lower specificity with those characterized by a high specificity combined with a lower sensitivity. Such an approach already yielded excellent results for CD prediction, where a panel of 51 serum antibodies and proteins, developed on a large cohort (n = 400), was demonstrated as being able to predict CD diagnosis within a year with an 87% accuracy [145].

Author Contributions: Conceptualization, M.K.-K. and K.N.; methodology, M.K.-K., K.N., M.B., and R.K.; formal analysis, M.K.-K. and K.N.; investigation, M.K.-K., K.N., R.K., and M.B.; writing—original draft preparation, M.K.-K., K.N., and R.K.; writing—review and editing, M.K.-K., K.N., and R.K.; validation, M.K.-K., K.N., R.K., and M.B.; visualization, M.K.-K. and K.N.; supervision, M.K.-K. and K.N.; funding acquisition, K.N. and R.K. All authors have read and agreed to the published version of the manuscript.

Funding: The APC was funded by Wroclaw Medical University, SUB.C130.20.031.

Acknowledgments: The authors would like to thank Angelica Zielinski for proofreading our manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Colombel, J.F.; Mahadevan, U. Inflammatory bowel disease 2017: Innovations and changing paradigms. Gastroenterology 2017, 152, 309–312. [CrossRef]
2. deSouza, H.; Fiocchi, C. Network medicine: A mandatory next step for inflammatory bowel disease. Inflam. Bowel Dis. 2018, 4, 671–679. [CrossRef] [PubMed]
3. Annese, V.; Daperno, M.; Rutter, M.D.; Amiot, A.; Bossuyt, P.; East, J.; Ferrante, M.; Götz, M.; Katsanos, K.H.; Kießlich, R.; et al. European evidence based consensus for endoscopy in inflammatory bowel disease. *J. Crohn’s Colitis* 2013, 7, 982–1018. [CrossRef] [PubMed]

4. Froslie, K.F.; Jahnsen, J.; Moum, B.A.; Vatn, M.H.; IBSEN Group. Mucosal healing in inflammatory bowel disease: Results from a Norwegian population-based cohort. *Gastroenterology* 2007, 133, 412–422. [CrossRef]

5. Ardizzzone, S.; Cassinotti, A.; Duca, F.; Mazzali, C.; Penati, C.; Manes, G.; Marmo, R.; Massari, A.; Molteni, P.; Miconi, G.; et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. *Clin. Gastroenterol. Hepatol.* 2011, 9, 483–489. [CrossRef] [PubMed]

6. Colombel, J.F.; Rutgeerts, P.; Reinisch, W.; Esser, D.; Wang, Y.; Lang, Y.; Marano, C.W.; Strauss, R.; Oddens, B.J.; Feagan, B.G.; et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. *Gastroenterology* 2011, 141, 1194–1201. [CrossRef] [PubMed]

7. Rutter, M.; Saunders, B.; Wilkinson, K.; Rumbles, S.; Schofield, G.; Kamm, M.; Williams, C.; Price, A.; Talbot, I.; Forbes, A. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. *Gastroenterology* 2004, 126, 451–459. [CrossRef] [PubMed]

8. Rutter, M.; Saunders, B.P.; Wilkinson, K.H.; Rumbles, S.; Schofield, G.; Kamm, M.A.; Williams, C.B.; Price, A.B.; Talbot, I.C.; Forbes, A. Cancer surveillance in longstanding ulcerative colitis: Endoscopic appearances help predict cancer risk. Gut 2004, 53, 1813–1816. [CrossRef]

9. Peyrin-Biroulet, L.; Sandborn, W.; Sands, B.E.; Reinisch, W.; Bemelman, W.; Bryant, R.V.; D’Haens, G.; Dotan, I.; Dubinsky, M.; Feagan, B.; et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for treat-to-target. *Am. J. Gastroenterol.* 2015, 110, 1324–1338. [CrossRef]

10. Shah, S.C.; Colombel, J.F.; Sands, B.E.; Narula, N. Systematic review with meta-analysis: Mucosal healing is associated with improved long-term outcomes in Crohn’s disease. *Aliment. Pharmacol. Ther.* 2016, 43, 317–333. [CrossRef]

11. Reinkink, A.R.; Lee, T.C.; Higgins, P.D. Endoscopic mucosal healing predicts favorable clinical outcomes in inflammatory bowel disease: A meta-analysis. *Inflamm. Bowel Dis.* 2016, 22, 1859–1869. [CrossRef]

12. Hanauer, S.B.; Feagan, B.G.; Lichtenstein, G.R.; Mayer, L.F.; Schreiber, S.; Colombel, J.F.; Rachmilewitz, D.; Wolf, D.C.; Olson, A.; Bao, W.; et al. Maintenance infliximab for Crohn’s disease: The ACCENT I randomised trial. *Lancet* 2002, 359, 1541–1549. [CrossRef]

13. Colombel, J.F.; Sandborn, W.J.; Reinisch, W.; Mantzaris, G.J.; Kornbluth, A.; Rachmilewitz, D.; Lichtiger, S.; D’Haens, G.; Diamond, R.H.; Broussard, D.L.; et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. *N. Engl. J. Med.* 2010, 362, 1383–1395. [CrossRef] [PubMed]

14. Sandborn, W.; Colombel, J.F.; Rutgeerts, P.; Yang, M.; Lomax, K.; Pollack, P.; Thakkar, R.; Canez, A.; Chen, N.; Chao, J.; et al. Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn’s disease: Data from EXTEND. *Am. J. Gastroenterol.* 2010, 105, S434–S435.

15. Neurath, M.F.; Travis, S.P.L. Mucosal healing in inflammatory bowel diseases: A systemic review. *Gut* 2012, 61, 1619–1635. [CrossRef] [PubMed]

16. Schroeder, K.W.; Tremaine, W.J.; Ilstrup, D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. *N. Engl. J. Med.* 1987, 317, 1625–1629. [CrossRef] [PubMed]

17. Rutgeerts, P.; Sandborn, W.J.; Feagan, B.G.; Reinisch, W.; Olson, A.; Johanns, J. Infliximab for induction and maintenance therapy for ulcerative colitis. *N. Engl. J. Med.* 2005, 353, 2462–2476. [CrossRef]

18. Maaser, C.; Sturm, A.; Vavricka, S.R.; Kucharzik, T.; Fiorino, G.; Annese, V.; Calabrese, E.; Baumgart, D.C.; Bettenworth, D.; Borralho Nunes, P.; et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: Initial diagnosis, monitoring of known IBD, detection of complications. *J. Crohn’s Colitis* 2019, 13, 144–164. [CrossRef]

19. Sturm, A.; Maaser, C.; Calabrese, E.; Annese, V.; Fiorino, G.; Kucharzik, T.; Vavricka, S.R.; Verstockt, B.; van Rheenen, P.; Tolan, D.; et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. *J. Crohn’s Colitis* 2019, 13, 273–284. [CrossRef]

20. Matsuoka, K.; Kobayashi, T.; Ueno, F.; Matsui, T.; Hirai, F.; Inoue, N.; Kato, J.; Kobayashi, K.; Koganei, K.; Kunisaki, R.; et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. *J. Gastroenterol.* 2018, 53, 305–353. [CrossRef]
21. Travis, S.P.; Schnell, D.; Krzeski, P.; Abreu, M.T.; Altman, D.G.; Colombel, J.F.; Feagan, B.G.; Hanauer, S.B.; Lichtenstein, G.R.; Marteau, P.R.; et al. Reliability and initial validation of the Ulcerative Colitis Endoscopic Index of Severity. *Gastroenterology* 2013, 145, 987–995. [CrossRef] [PubMed]

22. Samuel, S.; Bruining, D.H.; Loftus, E.V., Jr.; Thia, K.T.; Schroeder, K.W.; Tremaine, W.J.; Faubion, W.A.; Kane, S.V.; Pardi, D.S.; de Groen, P.C.; et al. Validation of the ulcerative colitis colonoscopy index of severity and its correlation with disease activity measures. *Clin. Gastroenterol. Hepatol.* 2013, 11, 49–54. [CrossRef] [PubMed]

23. Mary, J.Y.; Modigliani, R. Development and validation of an endoscopic index of the severity for Crohn’s disease: A prospective multicentre study. *Gut* 1989, 30, 983–989. [CrossRef] [PubMed]

24. Daperno, M.; D’Haens, G.; Van Assche, G.; Baert, F.; Bulois, P.; Maunoury, V.; Sostegni, R.; Rocca, R.; Pera, A.; Gevers, A.; et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: The SES-CD. *Gastrointest. Endosc.* 2004, 60, 505–512. [CrossRef]

25. Sipponen, T.; Nuutinen, H.; Turunen, U.; Färkkilä, M. Endoscopic evaluation of Crohn’s disease activity: Comparison of the CDEIS and the SES-CD. *Inflamm. Bowel Dis.* 2010, 16, 2131–2136. [CrossRef] [PubMed]

26. af Björkesten, C.G.; Nieminen, U.; Turunen, U.; Arkkila, P.; Sipponen, T.; Färkkilä, M. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn’s disease. *Scand. J. Gastroenterol.* 2012, 47, 528–537. [CrossRef]

27. Ayling, R.M.; Kok, K. Fecal calprotectin. *Adv. Clin. Chem.*

28. D’Haens, G.; Ferrante, M.; Vermeire, S.; Baert, F.; Noman, M.; Moortgat, L.; Geens, P.; Iwens, D.; Aerdens, I.; Van Assche, G.; et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. *Inflamm. Bowel Dis.* 2012, 18, 2218–2224. [CrossRef]

29. Ricanek, P.; Brackmann, S.; Perminow, G.; Lyckander, L.G.; Sponheim, J.; Holme, O.; Høie, O.; Rydning, A.; Vatn, M.H.; IBSEN II Study Group. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers. *Scand. J. Gastroenterol.* 2011, 46, 1081–1091. [CrossRef]

30. Schoepfer, A.M.; Beglinger, C.; Straumann, A.; Trummerl, M.; Vavricka, S.R.; Bruegger, L.E.; Seibold, F. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s Disease (SES-CD) than CRP, blood leukocytes, and the CDAI. *Am. J. Gastroenterol.* 2010, 105, 162–169. [CrossRef]

31. Schoepfer, A.M.; Beglinger, C.; Straumann, A.; Trummerl, M.; Renzulli, P.; Seibold, F. Ulcerative colitis: Correlation of the Rachmilewitz Endoscopic Activity Index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. *Inflamm. Bowel Dis.* 2009, 15, 1851–1858. [CrossRef] [PubMed]

32. Jusu, V.; Chaparro, M.; Gisbert, J.P. Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease. *Dig. Liver Dis.* 2018, 50, 353–359. [CrossRef] [PubMed]

33. Sipponen, T.; Björksten, C.G.; Färkkilä, M.; Nuutinen, H.; Savilahhti, E.; Kolhu, K.L. Fecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn’s disease treatment. *Scand. J. Gastroenterol.* 2010, 45, 325–331. [CrossRef] [PubMed]

34. Monteiro, S.; Dias de Castro, F.; Leite, S.; Moreir, M.H.; Cotter, J. Low fecal calprotectin predicts clinical remission in Crohn’s disease patients: The simple answer to a challenging question. *Scand. J. Gastroenterol.* 2019, 54, 49–54. [CrossRef]

35. Shimoyama, T.; Yamamoto, T.; Umegae, S.; Shimoyama, M. Fecal calprotectin level for assessing endoscopic activity and predicting future clinical course in patients with moderately active ulcerative colitis undergoing granulomonyctapheresis: A prospective cohort study. *BMJ Gastroenterol.* 2018, 18, 120. [CrossRef]

36. De Vos, M.; Dewit, O.; D’Haens, G.; Baert, F.; Fontaine, F.; Vermeire, S.; Franchimont, D.; Moreels, T.; Staessen, D.; Terriere, L.; et al. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis. *J. Crohn’s Colitis* 2012, 6, 557–562. [CrossRef]

37. Wei, S.C.; Tung, C.C.; Meng, M.T.; Wong, J.M. Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring. *Intest. Res.* 2018, 16, 546–553. [CrossRef]

38. Vinding, K.K.; Elsberg, H.; Thorkilgaard, T.; Belard, E.; Pedersen, N.; Elkaier, M.; Marker, D.; Carlsen, K.; Burisch, J.; Munkholm, P. Fecal calprotectin measured by patients at home using smartphones—a new clinical tool in monitoring patients with inflammatory bowel disease. *Inflamm. Bowel Dis.* 2016, 22, 336–344. [CrossRef]
39. Stawczyk-Eder, K.; Eder, P.; Lykowska-Szuber, L.; Kręla-Kazmierczak, I.; Klimczak, K.; Szymczak, A.; Szachta, P.; Katulska, K.; Linke, K. Is faecal calprotectin equally useful in all Crohn’s disease locations? A prospective, comparative study. Arch. Med. Sci. 2015, 11, 353–361. [CrossRef]

40. Gece, K.B.; Brandse, J.F.; van Wilpe, S.; Löwenberg, M.; Ponsioen, C.; van den Brink, G.; D’Haens, G. Impact of disease location on fecal calprotectin levels in Crohn’s disease. Scand. J. Gastroenterol. 2015, 50, 841–847. [CrossRef]

41. Goutorbe, F.; Goutte, M.; Minet-Quinard, R.; Boucher, A.-L.; Pereira, B.; Bommelaer, G.; Buissona, A. Endoscopic factors influencing fecal calprotectin value in Crohn’s disease. J. Crohn’s Colitis 2015, 9, 1113–1119. [CrossRef] [PubMed]

42. Carlsen, K.; Buhl, L.; Elsberg, H.; Maagaard, L.; Thorkilgaard, T.; Wergeland, S.; Jakobsen, C.; Wewer, V.; Florholmen, J.; Goll, R.; et al. The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis. Scand. J. Gastroenterol. 2016, 53, 825–830. [CrossRef]

43. Jha, A.K.; Chaudhary, M.; Dayal, V.M.; Kumar, A.; Jha, S.K.; Jha, P.; Purkayastha, S.; Ranjan, R. Optimal cut-off value of fecal calprotectin for the evaluation of ulcerative colitis: An unsolved issue? JGH Open 2018, 2, 207–213. [CrossRef]

44. Mak, W.Y.; Buisson, A.; Andersen, M.J.; Lei, D.; Pekow, J.; Cohen, R.D.; Kahr, S.A.; Pereira, B.; Rubin, D.T. Fecal calprotectin in assessing endoscopic and histological remission in patients with ulcerative colitis. Dig. Dis. Sci. 2018, 63, 1294–1301. [CrossRef] [PubMed]

45. Mine, S.; Takeishima, F.; Akazawa, Y.; Matsushima, K.; Minami, H.; Yamaguchi, N.; Ohnita, K.; Isomoto, H.; Nakao, K. Correlation of faecal markers with magnifying endoscopic stratification in patients with ulcerative colitis who are in clinical remission. Digestion 2018, 97, 82–89. [CrossRef]

46. Walsh, A.; Kormilitzin, A.; Hinds, C.; Sexton, V.; Brain, O.; Keshav, S.; Uhlig, H.; Geddes, J.; Goodwin, G.; Peters, M.; et al. Defining faecal calprotectin thresholds as a surrogate for endoscopic and histological disease activity in ulcerative colitis–a prospective analysis. J. Crohn’s Colitis 2018, 13, 424–430. [CrossRef]

47. Chen, J.M.; Liu, T.; Gao, S.; Tong, X.D.; Deng, F.H.; Nie, B. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China. World J. Gastroenterol. 2017, 23, 8235–8247. [CrossRef]

48. Kostas, A.; Siakavellas, S.I.; Kosmidis, C.; Takou, A.; Nikou, J.; Maropoulos, G.; Vlachogiannakos, J.; Papatheodoridis, G.V.; Papaconstantinou, I.; Bamias, G. Fecal calprotectin measurement is a marker of short term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World J. Gastroenterol. 2017, 23, 7387–7396. [CrossRef]

49. Lee, S.H.; Kim, M.J.; Chang, K.; Song, E.M.; Hwang, S.W.; Park, S.H.; Yang, D.H.; Kim, K.J.; Byeon, J.S.; Myung, S.J.; et al. Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis. BMC Gastroenterol. 2017, 17, 110. [CrossRef]

50. Patel, A.; Panchal, H.; Dubinsky, M.C. Fecal Calprotectin Levels Predict Histological Healing in Ulcerative Colitis. Inflamm. Bowel Dis. 2017, 23, 1600–1604. [CrossRef]

51. Hiraoka, S.; Takahama, S.; Inokuchi, T.; Nakarai, A.; Takahara, M.; Harada, K.; Seki, Y.; Watanabe, K.; Kato, J.; Okada, H. The novel latex agglutination turbidimetric immunoassay system for simultaneous measurements of calprotectin and hemoglobin in feces. Intest. Res. 2018. [CrossRef] [PubMed]

52. Zittan, E.; Kelly, O.B.; Kirsch, R.; Milgrom, R.; Burns, J.; Nguyen, G.C.; Croitoru, K.; Van Assche, G.; Silverberg, M.S.; Steinhart, A.H. Low fecal calprotectin correlates with histological remission and mucosal healing in ulcerative colitis and colonic Crohn’s disease. Inflamm. Bowel Dis. 2016, 22, 623–630. [CrossRef] [PubMed]

53. Langhorst, J.; Boone, J.; Lauche, R.; Rueffer, A.; Dobos, G. Faecal lactoferrin, calprotectin, PMN-elastase, CRP, and white blood cell count as indicators for mucosal healing and clinical course of disease in patients with mild to moderate ulcerative colitis: Post hoc analysis of a prospective clinical trial. J. Crohn’s Colitis 2016, 10, 786–794. [CrossRef] [PubMed]

54. Lin, W.C.; Wong, J.M.; Tung, C.C.; Lin, C.P.; Chou, J.W.; Wang, H.Y.; Shieh, M.J.; Chang, C.H.; Liu, H.H.; Wei, S.C. Taiwan Society of Inflammatory Bowel Disease Multicenter Study. Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients. World J. Gastroenterol. 2015, 21, 13566–13573. [CrossRef]
55. Lobaton, T.; Rodriguez-Moranta, F.; Lopez, A.; Sanchez, E.; Rodriguez-Alonso, L.; Guardiola, J. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis. Inflamm. Bowel Dis. 2013, 19, 1034–1042. [CrossRef]

56. Nancey, S.; Boscheti, G.; Moussata, D.; Cotte, E.; Peyras, J.; Cuerq, C.; Haybrard, J.; Charlois, A.-L.; Mialon, A.; Chauvenet, M.; et al. Neopterin is a novel fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases. Inflamm. Bowel Dis. 2013, 19, 1043–1052. [CrossRef]

57. Onal, I.K.; Beyazit, Y.; Sener, B.; Savuk, B.; Oz Etik, D.; Sayili, A.; Oztas, E.; Torun, S.; Ozderin Ozin, Y.; Tun Demrel, B.; et al. The value of fecal calprotectin as a marker of intestinal inflammation in patients with ulcerative colitis. Turk. J. Gastroenterol. 2012, 23, 509–514. [CrossRef]

58. Schoepfer, A.M.; Beglinger, C.; Straumann, A.; Safroneeva, E.; Romero, Y.; Armstrong, D.; Schmidt, C.; Trummer, M.; Pittet, V.; Vavricka, S.R. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm. Bowel Dis. 2013, 19, 332–341. [CrossRef]

59. Falvey, J.D.; Hoskin, T.; Berrie Meijer, B.; Ashcroft, A.; Walmsley, R.; Day, A.S.; Gearry, R.B. Disease activity assessment in IBD: Clinical indices and biomarkers fail to predict endoscopic remission. Inflamm. Bowel Dis. 2015, 21, 824–831. [CrossRef]

60. Kristensen, V.; Klepp, P.; Cvancerova, M.; Reseth, A.; Skar, V.; Moum, B. Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin. J. Crohn’s Colitis 2015, 9, 164–169. [CrossRef]

61. Scagliarini, M.; Cardamone, C.; Liverania, E.; Ugolini, G.; Festia, D.; Bazzofa, F.; Belluzzo, A. Clinical application of faecal calprotectin in ulcerative colitis patients. Eur. J. Gastroenterol. Hepatol. 2015, 27, 1418–1424. [CrossRef]

62. Takashima, S.; Kato, J.; Hiraoka, S.; Nak, A.; Takei, D.; Inokuchi, T.; Sugihara, Y.; Takahara, M.; Harada, K.; Okada, H.; et al. Evaluation of mucosal healing in ulcerative colitis by fecal calprotectin vs. fecal immunochemical test. Am. J. Gastroenterol. 2015, 110, 873–880. [CrossRef] [PubMed]

63. Theede, K.; Holck, S.; Ibsen, P.; Ladelund, S.; Nordgaard-Lassen, I.; Nielsen, A.M. Level of fecal calprotectin correlates with endoscopic and histologic inflammation and identifies patients with mucosal healing of ulcerative colitis. Clin. Gastroenterol. Hepatol. 2015, 13, 1929–1936. [CrossRef] [PubMed]

64. Voiosu, T.; Bengus, A.; Dinu, R.; Voiosu, A.M.; Balanescu, P.; Bacu, C.; Diculescu, M.; Radu Voiosu, R.; Mateescu, B. Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: A prospective study. J. Gastrointest. Liver Dis. 2014, 23, 273–278. [CrossRef] [PubMed]

65. Yamaguchi, S.; Takeuchi, Y.; Arai, K.; Fukuda, K.; Kuroki, Y.; Asonuma, K.; Takahashi, H.; Saruta, M.; Yoshida, H. Fecal calprotectin is a clinically relevant biomarker of mucosal healing in patients with quiescent ulcerative colitis. J. Gastroenterol. Hepatol. 2016, 31, 93–98. [CrossRef]

66. Nakov, R.; Velikova, T.; Nakov, V.; Gerova, V.; Tankova, L. Serum trefoil factor 3 predicts disease activity in patients with ulcerative colitis. J. Gastrointest. Liver Dis. 2019, 28, 169–174. [CrossRef]

67. Hart, L.; Chavannes, M.; Kherad, O.; Maedler, C.; Mourad, N.; Marcus, V.; Afif, W.; Bitton, A.; Lakatos, P.L.; Brassard, P.; et al. Faecal calprotectin predicts endoscopic and histological activity in clinically quiescent ulcerative colitis. J. Crohn’s Colitis 2020, 14, 46–52. [CrossRef]

68. Karling, P.; Lundgren, D.; Eklöf, V.; Palmqvist, R.; Hultdin, J. Improved monitoring of inflammatory activity in patients with ulcerative colitis by combination of faecal tests for haemoglobin and calprotectin. Scand. J. Clin. Lab. Investig. 2019, 79, 341–346. [CrossRef]

69. Lee, Y.W.; Lee, K.M.; Lee, J.M.; Chung, Y.Y.; Kim, D.B.; Kim, Y.J.; Chung, W.C.; Paik, C.N. The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity. Korean J. Intern. Med. 2019, 34, 72–80. [CrossRef]

70. Ryu, D.G.; Kim, H.W.; Park, S.B.; Kang, D.H.; Choi, C.W.; Kim, S.J.; Nam, H.S. Clinical implications of fecal calprotectin and fecal immunochemical test on mucosal status in patients with ulcerative colitis. Medicine 2019, 98, e17080. [CrossRef]

71. Iwamoto, F.; Matsuoka, K.; Motobayashi, M.; Takenaka, K.; Kuno, T.; Tanaka, K.; Tsukui, Y.; Kobayashi, S.; Yoshida, T.; Fujii, T.; et al. Prediction of disease activity of Crohn’s disease through fecal calprotectin evaluated by balloon-assisted endoscopy. J. Gastroenterol. Hepatol. 2018, 33, 1984–1989. [CrossRef] [PubMed]
72. Lopes, S.; Andrade, P.; Afonso, J.; Cunha, R.; Rodrigues-Pinto, E.; Ramos, I.; Macedo, G.; Magro, F. Monitoring Crohn’s disease activity: Endoscopy, fecal markers and computed tomography enterography. *Ther. Adv. Gastroenterol.* **2018**, *11*, 1–12. [CrossRef] [PubMed]

73. Vázquez-Morón, J.M.; Pallarés-Manrique, H.; Machancoses, F.H.; Ramos-Lora, M.; Ruiz-Frutos, C. Accurate cut-offs for predicting endoscopic active disease and mucosal healing in Crohn’s disease with fecal calprotectin. *Rev. Esp. Enferm. Dig.* **2016**, *108*, 130–136. [CrossRef]

74. Arai, T.; Takeuchi, K.; Miyamura, M.; Ishikawa, R.; Yamada, A.; Katsumata, M.; Igarashi, Y.; Suzuki, Y. Level of fecal calprotectin correlates with severity of small bowel Crohn’s disease, measured by balloon-assisted enteroscopy and computed tomography enterography. *Clin. Gastroenterol. Hepatol.* **2017**, *15*, 56–62. [CrossRef] [PubMed]

75. Inokuchi, T.; Kato, J.; Hiraoka, S.; Takashima, S.; Nakarai, A.; Takei, D.; Sugihara, Y.; Takahara, M.; Kawano, S.; Harada, K.; et al. Fecal immunochemical test versus fecal calprotectin for prediction of mucosal healing in Crohn’s disease. *Inflamm. Bowel Dis.* **2016**, *22*, 1078–1085. [CrossRef]

76. Lobatón, T.; López-García, A.; Rodriguez-Moranta, F.; Ruiz, A.; Rodriguez, L.; Guardiola, J. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn’s disease. *J. Crohn’s Colitis* **2013**, *7*, e641–e651. [CrossRef]

77. Schaffer, T.; Schoepfer, A.M.; Seibold, F.; on behalf of the Swiss IBD Cohort Study Group. Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn’ disease activity. *J. Crohn’s Colitis* **2014**, *8*, 1125–1132. [CrossRef]

78. Karczewski, J.; Swora-Cwynar, E.; Rzymski, P.; Poniedziałek, B.; Adamski, Z. Selected biologic markers of inflammation and activity of Crohn’s disease. *Autoimmun. Rev.* **2015**, *14*, 318–327. [CrossRef] [PubMed]

79. Ma, C.; Lumb, R.; Walker, E.V.; Ishikawa, R.; Yamada, A.; Katsumata, M.; Igarashi, Y.; Suzuki, Y. Level of fecal calprotectin correlates with severity of small bowel Crohn’s disease, measured by balloon-assisted enteroscopy and computed tomography enterography. *Clin. Gastroenterol. Hepatol.* **2017**, *15*, 56–62. [CrossRef] [PubMed]

80. Theede, K.; Holck, S.; Ibsen, P.; Kallemose, T.; Nordgaard-Lassen, I.; Mertz Nielsen, A. Fecal calprotectin predicts relapse and histological mucosal healing in ulcerative colitis. *Inflamm. Bowel Dis.* **2016**, *22*, 1042–1048. [CrossRef]

81. Bodelier, A.G.L.; Jonkers, D.; van den Heuvel, T.; de Boer1, E.; Hameeteman, W.; Masclee, A.; Pierik, M.J. High Percentage of IBD patients with indefinite fecal calprotectin levels: Additional value of a combination score. *Dig. Dis. Sci.* **2017**, *62*, 465–472. [CrossRef] [PubMed]

82. Laserna-Mendieta, E.J.; Lucendo, A.J. Faecal calprotectin in inflammatory bowel diseases: A review focused on meta-analyses and routine usage limitations. *Clin. Chem. Lab. Med.* **2019**, *57*, 1295–1307. [CrossRef] [PubMed]

83. Meucci, G.; D’Incà, R.; Maieron, R.; Orzes, N.; Vecchi, M.; Visentini, D.; Minoli, G.; Dal Pont, E.; Zilli, M.; Benedetti, E.; et al. Diagnostic value of faecal calprotectin in unselected outpatients referred for colonoscopy: A multicenter prospective study. *Dig. Liver Dis.* **2010**, *42*, 191–195. [CrossRef] [PubMed]

84. Julsgaard, M.; Hvas, C.L.; Gearry, R.B.; Vestergaard, T.; Falllingborg, J.; Svenningsen, L.; Kjeldsen, J.; Sparrow, M.P.; Wildt, S.; Kelsen, J.; et al. Fecal calprotectin is not affected by pregnancy: Clinical implications for the management of pregnant patients with inflammatory bowel disease. *Inflamm. Bowel Dis.* **2017**, *23*, 1643–1649. [CrossRef]

85. Karczewski, J.; Swora-Cwynar, E.; Rzymski, P.; Poniedziałek, B.; Adamski, Z. Selected biologic markers of inflammation and activity of Crohn’s disease. *Autoimmun. Rev.* **2015**, *14*, 318–327. [CrossRef] [PubMed]

86. Lasson, A.; Stotzer, P.O.; Öhman, L.; Isaksson, S.; Sapnara, M.; Strid, H. The intra-individual variability of faecal calprotectin: A prospective study in patients with active ulcerative colitis. *J. Crohn’s Colitis* **2015**, *9*, 26–32. [CrossRef]

87. Toyonaga, T.; Kobayashi, T.; Nakano, M.; Saito, E.; Umada, S.; Okabayashi, S.; Ozaki, R.; Hibi, T. Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome. *PLoS ONE* **2017**, *12*, e0185131. [CrossRef]
88. Acevedoa, D.; Salvador, M.P.; Girbesa, J.; Estana, N. Fecal Calprotectin: A comparison of two commercial enzymoimmunoassays and study of fecal extract stability at room temperature. *J. Clin. Med. Res.* 2018, 10, 396–404. [CrossRef]

89. Amcoff, K.; Stridsberg, M.; Lampinen, M.; Magnuson, A.; Carlson, M.; Halfvarson, J. Clinical implications of assay-specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time. *Scand. J. Gastroenterol.* 2016, 52, 344–350. [CrossRef]

90. Moniuszko, A.; Głuszek, G.; Rydzewska, G. Rapid fecal calprotectin test for prediction of mucosal inflammation in ulcerative colitis and Crohn disease: A prospective cohort study. *Pol. Arch. Intern. Med.* 2017, 127, 312–318. [CrossRef]

91. Annaházi, A.; Molnár, T.; Farkas, K.; Rosztóczy, A.; Izbéki, F.; Gece, K.; Inczefi, O.; Nagy, F.; Földesi, I.; Szűcs, M.; et al. Fecal MMP-9: A new noninvasive differential diagnostic and activity marker in ulcerative colitis. *Inflamm. Bowel Dis.* 2013, 19, 316–320. [CrossRef] [PubMed]

92. Buisson, A.; Vazeille, E.; Minet-Quinard, R.; Goutte, M.; Bouvier, D.; Goutorbe, F.; Pereira, B.; Barnich, N.; Bommelaer, G. Fecal matrix metalloproteinase-9 and lipocalin-2 as biomarkers in detecting endoscopic activity in patients with inflammatory bowel diseases. *J. Clin. Gastroenterol.* 2018, 52, e53–e62. [CrossRef] [PubMed]

93. Farkas, K.; Saródi, Z.; Bálint, I.; Földesi, I.; Tiszlavicz, L.; Szűcs, M.; Nyári, T.; Tajti, J.; Nagy, F.; Szepes, Z.; et al. The diagnostic value of a new fecal marker, matrix metalloproteinase-9, in different types of inflammatory bowel diseases. *J. Crohn’s Colitis* 2015, 9, 231–237. [CrossRef] [PubMed]

94. Klimczak, K.; Lykowska-Szuber, L.; Eder, P.; Krela-Kazmierczak, I.; Stawczyk-Eder, K.; Szymczak, A.; Taguchi, H.; et al. The diagnostic usefulness of fecal lactoferrin in the assessment of Crohn’s disease activity. *Eur. J. Intern. Med.* 2015, 26, 623–627. [CrossRef]

95. Beyazit, Y.; Koklu, S.; Tas, A.; Purnak, T.; Sayilir, A.; Kurt, M.; Turhan, T.; Suvak, B.; Torun, S.; et al. Serum adenosine deaminase activity as a predictor of disease severity in ulcerative colitis. *J. Crohn’s Colitis* 2012, 6, 102–107. [CrossRef]

96. de Bruyn, M.; Arijs, I.; Wollants, W.J.; Machiels, K.; Van Steen, K.; Van Assche, G.; Ferrante, M.; Rutgeerts, P.; Vermeire, S.; Opdenakker, G. Neutrophil gelatinase B-associated lipocalin and matrix metalloproteinase-9 complex as a surrogate serum marker of mucosal healing in ulcerative colitis. *Inflamm. Bowel Dis.* 2014, 20, 1198–1207. [CrossRef]

97. Dranga, M.; Mihai, C.; Drug, V.; Dumitrescu, G.; Prelipcean, C.C. A rapid test for assessing disease activity in ulcerative colitis. *Turk. J. Gastroenterol.* 2016, 27, 149–155. [CrossRef] [PubMed]

98. Hassan, E.A.; Ramadan, H.K.; Ismael, A.A.; Mohamed, K.F.; El-Attar, M.M.; Alhelali, I. Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis. *Saad. J. Gastroenterol.* 2017, 23, 238–245. [CrossRef]

99. Jung, Y.S.; Park, J.J.; Kim, S.W.; Hong, S.P.; Kim, T.I.; Kim, W.H.; Cheon, J.H. Correlation between soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) expression and endoscopic activity in inflammatory bowel diseases. *Dig. Liver Dis.* 2012, 44, 897–903. [CrossRef] [PubMed]

100. Neubauer, K.; Matusiewicz, M.; Bednarz-Misa, I.; Gorska, S.; Gamian, A.; Krzystek-Korpacka, M. Diagnostic potential of systemic eosinophil-associated cytokines and growth factors in IBD. *Gastroenterol. Res. Pract.* 2018, 2018, 7265812. [CrossRef]
105. Rosenberg, L.; Lawlor, G.O.; Zenlea, T.; Goldsmith, J.D.; Gifford, A.; Falchuk, K.R.; Wolf, J.L.; Cheifetz, A.S.; Robson, S.C.; Moss, A.C. Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. *Inflamm. Bowel Dis.* 2013, 19, 779–784. [CrossRef]

106. Samant, H.; Desai, D.; Abraham, P.; Joshi, A.; Gupta, T.; Dherai, A.; Ashvaiad, T. Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease. *Indian J. Gastroenterol.* 2015, 34, 431–435. [CrossRef]

107. Shinzaki, S.; Matsuoka, K.; Iijima, H.; Mizuno, S.; Serada, S.; Fujimoto, M.; Arai, N.; Koyama, N.; Morii, E.; Watanabe, M.; et al. Leucine-rich Alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis. *J. Crohn’s Colitis* 2017, 11, 84–91. [CrossRef]

108. Tran, D.H.; Wang, J.; Ha, C.; Ho, W.; Mattai, S.A.; Oikonomopoulos, A.; Weiss, G.; Lacey, P.; Cheng, M.; Shieh, C.; et al. Circulating cathelicidin levels correlate with mucosal disease activity in ulcerative colitis, risk of intestinal stricture in Crohn’s disease, and clinical prognosis in inflammatory bowel disease. *BMC Gastroenterol.* 2017, 17, 63. [CrossRef]

109. Uchihara, M.; Kato, J.; Tsuda, S.; Yoshida, T.; Maekita, T.; Iguchi, M.; Kitano, M. Blood biomarkers reflect integration of severity and extent of endoscopic inflammation in ulcerative colitis. *JGH Open* 2017, 1, 98–104. [CrossRef]

110. Yoon, J.Y.; Park, S.J.; Hong, S.P.; Kim, T.I.; Kim, W.H.; Cheon, J.H. Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis. *Dig. Dis. Sci.* 2014, 59, 829–837. [CrossRef]

111. de Bruyn, M.; Arijs, I.; De Hertogh, G.; Ferrante, M.; Van Assche, G.; Rutgeerts, P.; Vermeire, S.; Opdenakker, G. Serum neutrophil gelatinase B-associated lipocalin and matrix metalloproteinase-9 complex as a surrogate marker for mucosal healing in patients with Crohn’s disease. *J. Crohn’s Colitis* 2015, 9, 1079–1087. [CrossRef] [PubMed]

112. Hosomi, S.; Hamagami, H.; Itani, S.; Yukawa, T.; Otani, K.; Nagami, Y.; Tanaka, E.; Taera, K.; Kamata, N.; Tanigawa, T.; et al. Sepsis Markers Soluble IL-2 Receptor and soluble CD14 subtype as potential biomarkers for complete mucosal healing in patients with inflammatory bowel disease. *J. Crohn’s Colitis* 2018, 12, 87–95. [CrossRef] [PubMed]

113. Ishihara, S.; Tada, Y.; Kawashima, K.; Kataoka, M.; Sonoyama, H.; Yamashita, N.; Oka, A.; Kusunoki, R.; Fukuba, N.; Mishima, Y.; et al. Serum amyloid A level correlated with endoscopic findings in patients with Crohn’s disease-Possible biomarker for evaluating mucosal healing. *Dig. Liver Dis.* 2018, 50, 553–558. [CrossRef] [PubMed]

114. Miranda-García, P.; Chaparro, M.; Gisbert, J.P. Correlation between serological biomarkers and endoscopic activity in patients with inflammatory bowel disease. *Gastroenterol. Hepatol.* 2016, 39, 508–515. [CrossRef]

115. Yarur, A.J.; Quintero, M.A.; Jain, A.; Czul, F.; Barkin, J.S.; Abreu, M.T. Serum Amyloid A as a surrogate marker for mucosal and histologic inflammation in patients with Crohn’s disease. *Inflamm. Bowel Dis.* 2017, 23, 158–164. [CrossRef]

116. Mańkowska-Wierzbicka, D.; Swora-Cwynar, E.; Poniedziałek, B.; Adamski, Z.; Dobrowolska, A.; Karczewski, J. Usefulness of selected laboratory markers in ulcerative colitis. *Eur. Cytokine Netw.* 2015, 26, 26–37. [CrossRef]

117. Moein, S.; Qujeq, D.; Vaghar Tabari, M.; Kashifard, M.; Hajian-Tilaki, K. Diagnostic accuracy of fecal calprotectin in assessing the severity of inflammatory bowel disease: From laboratory to clinic. *Casp. J. Intern. Med.* 2017, 8, 178–182. [CrossRef]

118. Meuwis, M.A.; Vernier-Massouille, G.; Grimaud, J.C.; Bouhnik, Y.; Laharie, D.; Piver, E.; Seidel, L.; Colombel, J.F.; Louis, E.; GETAID (Groupe d’Étude Thérapeutique Des Affections Inflammatoires Digestives). Serum calprotectin as a biomarker for Crohn’s disease. *J. Crohn’s Colitis* 2013, 7, e678–e683. [CrossRef]

119. Matusiewicz, M.; Neubauer, K.; Bednarz-Misa, I.; Gorska, S.; Krzyztek-Korpacka, M. Systemic interleukin-9 in inflammatory bowel disease: Association with mucosal healing in ulcerative colitis. *World J. Gastroenterol.* 2017, 23, 4039–4046. [CrossRef]

120. Wu, H.M.; Wei, J.; Li, J.; Wang, K.; Ye, L.; Qi, Y.; Yuan, B.S.; Yang, Y.L.; Zhao, L.; Yang, Z.; et al. Serum procalcitonin as a potential early predictor of short-term outcomes in acute severe ulcerative colitis. *Dig. Dis. Sci.* 2019, 64, 3263–3273. [CrossRef]
121. Koido, S.; Ohkusa, T.; Takakura, K.; Odahara, S.; Tsukinaga, S.; Yukawa, T.; Mitobe, J.; Kajihara, M.; Uchiyama, K.; Arakawa, H.; et al. Clinical significance of serum procalcitonin in patients with ulcerative colitis. World J. Gastroenterol. 2013, 19, 8335–8341. [CrossRef] [PubMed]

122. Oussalah, A.; Laurent, V.; Bruot, O.; Guéant, J.L.; Régent, D.; Bigard, M.A.; Peyrin-Biroulet, L. Additional benefit of procalcitonin to C-reactive protein to assess disease activity and severity in Crohn’s disease. Aliment. Pharmacol. Ther. 2010, 32, 1135–1144. [CrossRef] [PubMed]

123. Zezos, P.; Papaioannou, G.; Nikolaidis, N.; Patsiaoura, K.; Vassiliadis, T.; Mpounparnis, A.; Giouleme, O.; Evgenidis, N. Elevated markers of thrombin generation and fibrinolysis in patients with active and quiescent ulcerative colitis. Med. Sci. Monit. 2009, 15, CR563–CR572. [PubMed]

124. Díaz-Jiménez, D.; Núñez, L.E.; Beltrán, C.J.; Candel, E.; Suazo, C.; Alvarez-Lobos, M.; González, M.J.; Hermoso, M.A.; Quera, R. Soluble ST2: A new and promising activity marker in ulcerative colitis. World J. Gastroenterol. 2011, 17, 2181–2190. [CrossRef]

125. Matusiewicz, M.; Neubauer, K.; Lewandowska, P.; Gamian, A.; Krzystek-Korpacka, M. Reduced transferrin levels in active inflammatory bowel disease. Biomed. Res. Int. 2017, 2017, 9541370. [CrossRef] [PubMed]

126. Algaba, A.; Linares, P.M.; Fernández-Contreras, M.E.; Ordoñez, A.; Trápaga, J.; Guerra, I.; Chaparro, M.; de la Poza, G.; Gisbert, J.P.; Bermejo, F. Relationship between levels of angiogenic and lymphangiogenic factors and the endoscopic, histological activity, and acute-phase reactants in patients with inflammatory bowel disease. J. Crohn’s Colitis 2013, 7, e569–e579. [CrossRef]

127. Boga, S.; Alkim, H.; Koksal, A.R.; Ozagari, A.A.; Bayram, M.; Tekin Neijmann, S.; Sen, I.; Alkim, C. Serum ST2 in inflammatory bowel disease: A potential biomarker for disease activity. J. Investig. Med. 2016, 64, 1016–1024. [CrossRef]

128. Algaba, A.; Linares, P.M.; Fernández-Contreras, M.E.; Ordoñez, A.; Trápaga, J.; Guerra, I.; Chaparro, M.; de la Poza, G.; Gisbert, J.P.; Bermejo, F. Relationship between levels of angiogenic and lymphangiogenic factors and the endoscopic, histological activity, and acute-phase reactants in patients with inflammatory bowel disease. J. Crohn’s Colitis 2013, 7, e569–e579. [CrossRef]

129. Zezos, P.; Papaioannou, G.; Nikolaidis, N.; Patsiaoura, K.; Vassiliadis, T.; Mpounparnis, A.; Giouleme, O.; Evgenidis, N. Elevated markers of thrombin generation and fibrinolysis in patients with active and quiescent ulcerative colitis. Med. Sci. Monit. 2009, 15, CR563–CR572. [PubMed]

130. Budzynska, A.; Gawron-Kiszka, M.; Nowakowska-Dulawa, E.; Spiewak, J.; Perez, T.; Gonzalez, M.J.; Simian, D.; Hermoso, M.A.; Quera, R. Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution. BMC Gastroenterol. 2016, 16, 103. [CrossRef]

131. Budzynska, A.; Gawron-Kiszka, M.; Nowakowska-Dulawa, E.; Spiewak, J.; Lesinska, M.; Kukla, M.; Waluga, M.; Hartleb, M. Serum neutrophil gelatinase-associated lipocalin (NGAL) correlates with clinical and endoscopic activity in ulcerative colitis but fails to predict activity in Crohn’s disease. J. Physiol. Pharmacol. 2017, 68, 859–865.

132. Neubauer, K.; Bednarz-Misa, I.; Walecka-Zacharska, E.; Wierzbiicki, J.; Agrawal, A.; Gamian, A.; Krzystek-Korpacka, M. Oversecretion and overexpression of nicotinamide phosphoribosyltransferase/Pre-B Colony-Enhancing Factor/Visfatin in inflammatory bowel disease reflects the disease activity, severity of inflammatory response and hypoxia. Int. J. Mol. Sci. 2019, 20, 166. [CrossRef] [PubMed]

133. Rodríguez-Perálvarez, M.L.; García-Sánchez, V.; Villar-Pastor, C.M.; González, R.; Iglesias-Flores, E.; Muntane, J.; Gómez-Camacho, F. Role of serum cytokine profile in ulcerative colitis assessment. Inflamm. Bowel Dis. 2012, 18, 1864–1871. [CrossRef] [PubMed]

134. Srivastava, S.; Kedia, S.; Kumar, S.; Pratap Mouli, V.; Dhand, R.; Tiwari, V.; Kurrey, L.; Pradhan, R.; Ahuja, V. Serum human trefoil factor 3 is a biomarker for mucosal healing in ulcerative colitis patients with minimal disease activity. J. Crohn’s Colitis 2015, 9, 575–579. [CrossRef] [PubMed]

135. Trejo-Vazquez, F.; Garza-Veloz, I.; Villela-Ramírez, G.A.; Ortiz-Castro, Y.; Mauricio-Saucedo, P.; Cardenas-Vargas, E.; Díaz-Baez, M.; Cid-Baez, M.A.; Castañeda-Miranda, R.; Ortiz-Rodriguez, J.M.; et al. Positive association between leptin serum levels and disease activity on endoscopy in inflammatory bowel disease: A case-control study. Exp. Ther. Med. 2018, 15, 3336–3344. [CrossRef]

136. Markanday, A. Acute Phase Reactants in Infections: Evidence-based review and a guide for clinicians. Open Forum Infect. Dis. 2015, 2, ofv098. [CrossRef]

137. Souli, I.; Touni, R.; Touil-Boukoffa, C. Overview of cytokines and nitric oxide involvement in immuno-pathogenesis of inflammatory bowel diseases. World J. Gastrointest. Pharmacol. Ther. 2016, 7, 353–360. [CrossRef]

138. Ljuca, F.; Gegic, A.; Salkic, N.N.; Pavlovic-Calic, N. Circulating cytokines reflect mucosal inflammatory status in patients with Crohn’s disease. Dig. Dis. Sci. 2010, 55, 2316–2326. [CrossRef]
138. Feng, T.; Chen, B.; Li, L.; Huang, S.; Ben-Horin, S.; Qu, Y.; Feng, R.; Li, M.; Mao, R.; He, Y.; et al. Serum interleukin 9 levels predict disease severity and the clinical efficacy of infliximab in patients with Crohn’s disease. *Inflamm. Bowel Dis.* 2017, 23, 1817–1824. [CrossRef]

139. Linares, P.M.; Algaba, A.; Urzainqui, A.; Guijarro-Rojas, M.; González-Tajuelo, R.; Garrido, J.; Chaparro, M.; Gisbert, J.P.; Bermejo, F.; Guerra, J.; et al. Ratio of circulating estrogen receptors beta and alpha (ERβ/ERα) indicates endoscopic activity in patients with Crohn’s disease. *Dig. Dis. Sci.* 2017, 62, 2744–2754. [CrossRef]

140. Yarur, A.J.; Jain, A.; Quintero, M.A.; Czul, F.; Deshpande, A.R.; Kerman, D.H.; Abreu, M.T. Inflammatory cytokine profile in Crohn’s disease nonresponders to optimal antitumor necrosis factor therapy. *J. Clin. Gastroenterol.* 2019, 53, 210–215. [CrossRef]

141. Nakov, R.; Velikova, T.; Nakov, V.; Ianiro, G.; Gerova, V.; Tankova, L. Serum trefoil factor 3 predicts disease activity in patients with ulcerative colitis. *Eur. Rev. Med. Pharmacol. Sci.* 2019, 23, 788–794. [CrossRef]

142. Arai, Y.; Arihiro, S.; Matsuura, T.; Kato, T.; Matsuoka, M.; Saruta, M.; Mitsunaga, M.; Matsuura, M.; Fujiwara, M.; Okayasu, I.; et al. Prostaglandin E-major urinary metabolite as a reliable surrogate marker for mucosal inflammation in ulcerative colitis. *Inflamm Bowel Dis* 2014, 20, 1208–1216. [CrossRef] [PubMed]

143. Ng, S.C.; Shi, H.Y.; Hamidi, N.; Tang, W.; Benchimol, E.I.; Panaccione, R.; Ghosh, S.; Wu, J.C.Y.; Chan, F.K.L.; Sung, J.J.Y.; et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. *Lancet* 2018, 390, 2769–2778. [CrossRef]

144. Boyapati, R.K.; Kalla, R.; Satsangi, J.; Ho, G.T. Biomarkers in Search of Precision Medicine in IBD. *Am. J. Gastroenterol.* 2016, 111, 1682–1690. [CrossRef] [PubMed]

145. Torres, J.; Petralia, F.; Sato, T.; Wang, P.; Telesco, S.E.; Choung, R.S.; Strauss, R.; Li, X.-J.; Laird, R.M.; Gutierrez, R.L.; et al. Serum biomarkers identify patients who will develop inflammatory bowel diseases up to 5 y before diagnosis. *Gastroenterology* 2020. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).